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SUMMARY
Ephrins (EFNs) are ccli surface ligands of Ephs, the largest family of celi-surface receptor
tvrosine kinases. The function of EfNs in the immune system has flot been well studied,
although some EfNs and Ephs are expressed at high levels on certain leukocytes. The data
presented here indicate that the EFNB subciass (EfNBs) and their receptors (EfNBRs) are
expressed in peripherai lymphocytes and monocytes/macrophages, with T celis being the
dominant EFNBs and EfNBRs ccli type. Solid phase EFNBs-Fc in the presence of
suboptimai anti-CD3 crosslinking enhanced T-ce!! responses in terms of proliferation.
activation marker expression, IfN-y production, and cytotoxic T-cetl activity. Afier
crosslinking, T ccli receptor and EFNBRs congregated into aggregated rafts, and this
provided a morpho!ogical basis for interaction between TCR and EFNBR signaling
pathways. further downstream, p38 and p44/42 MAPK vas activated by EFNBR
crosslinking. EFNBs, especially BI, and their receptors are also expressed in CD4CD8
double positive and CD$ single positive ceils, and to a lesser extent, in CD4 single positive
celis. Soiid phase EFNB1 effectively protected thymocyte from CD3-induced apoptosis,
whi!e soluble EFNB1 significantiy augmented such apoptosis. The effect of EFNB1 on
thymocyte survival was more significant on populations expressing higher levels of
EFNB1Rs. These resu!ts demonstrate that EfNBs and EfNBRs play pivotai roles in
modulating T ccli function and thymocyte deveiopment.
Key words: Eph; EFN: T cdl; Thymocyte; costimulation; T-cell deveiopment.
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Résumé
Les Ephrins (EfNs) sont un ligand membranaire de Ephs, la grande famille des récepteurs
tyrosine kinase. La fonction des EFNs n’est pas encore bien définie dans le système
immunitaire, mais certains EFNs et Ephs sont surexprimés dans les leucocytes. Les
résultats présentés ici indiquent que la sous-famille des EFNBs et leurs récepteurs sont
éxprimés dans les lymphocytes périphériques, les monocytes et les macrophages; dans les
cellules T, les EFNBs et EFNBRs dominent. En phase solide, les EFNBs-Fc. en présence
de concentrations suboptimales d’ anti-CD3 amplifient la prolifération, l’activation des
marqueurs d’expression. la production des IFN-g et l’activité cytotoxique des cellules T.
Après inter-réaction (crosslinking), les cellules T réceptrices et EfNBRs se rassemblent en
radeaux lipidiques. Ces derniers constituent une base morphologique pour l’interaction
entre le TCR et 1’ EfNBR menant à l’activation de leur voie de signalisation. En aval, les
p38 et p44742 MAPK sont activés par l’inter-réaction de EfNBR. Les EFNBs,
particulièrement EFNB 1. et leurs récepteurs sont également exprimés par les CD4CD8
double positifs, les CD8 positifs et, moins fortenment par les CD4 positifs. En phase solide,
EfNB1 protège efficacement les thymocytes suite à l’apoptose induite par CD3, même si
EfNB1 en phase soluble augmente considérablement l’induction de l’apoptose. L’effet de
EFNB1 sur la survie des thymocytes est plus significative sur les populations surexpnmant
les EFNB1Rs. Ces résultats démontrent que les EfNBs et EFNBRs jouent un rôle
primordial dans la modulation de la fonction des cellules T et aussi dans le developpement
des thymocytes.
Mots clé: Eph; EFN; T cell; Thymocyte; costimulation; T-cell development.
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INTRODUCTION
In multiceflular organisms, celis can interact with each other to achieve their biological
functions. The ccli surface receptors and their celi surface iigands are pivotai structures for
such cell-to-ceÏl communication. Receptor tyrosine kinases (RTK5) are a large group of celi
surface receptors that possess intrinsic cytoplasmic tyrosine kinase activity. Functionally,
they play critical roles in celi proliferation, differentiation, migration and metabolism.
There are several RTK families, such as the insulin, Eph, and the receptors for many growth
factors, including the epidermal growth factor, platelet-derived growth factor, fibroblast
growth factor and vascular endothelial growth factor. Ephs are the largest family of RTK,
with a total of 15 members belonging to two subclasses (EphAs and EphBs subfamilies).
They are membrane-bound glycoproteins and are activated by the binding of their cognate
ligands, ephrins (EfNs). EfNs consist of 9 members oftwo subclasses, EfNAs and EfNBs.
They are also membrane-bound. Both Ephs and EfNs can transduce the extracellular signai
to the cytoplasm, either by phosphorylating tyrosine residues on the receptors themselves
(autophosphorylation) andlor on downstrearn signaling proteins, playing their roles in
regulating various cellular activities.
In comparison to the extensive studies donc in the central newous system, far fewer efforts
have been made in understanding the function of Ephs and EfNs in the immune system. Our
work aims to enhance our knowledge on the function of EFNs and Ephs in immune
regulation.
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1.1. Eph receptors and EFNs Jigands
The term Eph originates from the name of a ce!! une, rythropoietin-producing human
hepatocellular carcinoma, from which the first member of the farnily was identified (1). The
!igands of Ephs, ephrins, may derive from two origins. One is the Greek word ejoros (or
ephoros), meaning overseer or contro!ler; the other is the abbreviation ofph fami!y receptor
interacting proteins (2).
Since the first Eph member, EphAl, was cloned (1), new members ofthis fami!y and their
ligands were rapidly discovered. Many different names have been given to a same member,
which is inconvenient for reference. In September 1996, a uniform nomenclature was
recommended at the “Molecular Biology of Axon Guidanc&’ workshop, and since then the
new name of these !argest RTK members have been wide!y adopted. A summarized
nomenclature has been posted at the following website: http://cbweb.med.harvard.edu/eph
nomenclature. To date, 9 members of EphAs (EphAl-9) and 6 members ofEphBs (EphBl
6) in the Eph family, and 6 members ofEfNAs (EFNA1-6) and 3 EFNBs (EfNB!-3) in the
EFN fami!y have been identified (3, 4). Such a classification (A and B subfami!ies) is based
on sequence simitarity and partner binding affinities. The members within each subclass
share different degrees of homology. for examp!e, the extracellular regions of EfNB 1 show
50% arnino acid identity with EfNB2, and 42% identity with EFNB3 (5). Detai!ed sequence
homology dendrograms of Eph receptors and EFN !igands can be viewed at the website:
http//cbweb. med. harvard. edtt/eph-noinenctature.
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1.1.1. Expression ofEFNBs and Eph receptors
The expression of Eph and EfN protein has been shown in various tissues of zebrafish,
xenopus, chicken ernbryos mice, rats and human (4). Physiologically, they are widely
expressed during development, being most abundant in the nervous system and, to a lesser
extent, in vascular endothelium and some specialized epithelia. They are also detected in
some tumor ceils or tumor-related tissues. The expression of Ephs and EfNs in various
organs, including immune ceils, is surnmarized in Table 1.
Table 1. Expression of Eph and EfN members
Name Expression in organs or tissues
EphAl In the embryonic or aduit mouse: the liver, lung, kidney, thymus, and
placenta (6, 7).
In aduit rat: the liver, lung, kidncy, testis (8), and thymus (9).
In human: high in the bladder, and small intestine; moderate in the lung, liver,
colon, kidney, thymus, prostate and testis; low in the brain, spleen, and utems
(10).
EphA2 In the embryonic mouse: at the early stage, neurogenic crest cells of the
facial, acoustic, and distal regions of limb bud mesenchyme; at later stage,
the cartilaginous model of the skeleton, tooth prirnordia, infundibular
component of the pituitary, various fetal tissue epithelia (11, 12, 13); high
levels in the developing lung, kidney, intestine, and salivary gland (14). In
adult mouse: the lung (11) and thymus (7).
In the aduit rat: high level in the lung, skin, small intestine, and ovary; low in
kidney, brain, spleen, submaxillary gland (15), and thymus (9).
In human: high level in the bladder, lung and kidney; moderate in the liver,
spleen, small intestine, uterus and thymus; low in the brain, prostate and testis
(10).
EphA3 In the embryonic mouse: the forebrain, midbrain, hindbrain, neural tube,
branchial arches (lst & 2nd), sornites, and limb buds (16).
In the adult mouse and rat: the brain (17, 18, 19) and thymus or thymocyte (7,
9). In human: high level in the utems, bladder and prostate; moderate in the
brain, lung and testis; low in the thymus, liver, spleen, small intestine and
kidney (10).
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EphA4 In the ernbryonic mouse: multiple sites of the developing central nervous
system, the striatum, ventricular zone of the cerebral cortex, hippocampus,
thalamus, cerebellum, facial nucleus, and anterior hom ofthe spinaL cord. In
the adult mouse: the hippocampus, cerebral cortex, striatum, thalamus,
granule layer of the cerebellum (14), fetal and adult B-lineage cells (20), and
thymus (7).
In rat: the adult brain (17) and thymus (9).
In human: high level in the brain and testis; moderate in kidney; low in the
thymus, heart, lung, spleen, pancreas, small intestine, muscle, placenta,
________
bladder, utems, prostate and bone marrow (10, 21).
EphA5 In the embiyonic mouse: the telencephalon, olfactory bulb, and retina. In
fetal and aduit mice: high expression at the hippocampus (22).
In the aduit rat: the hippocampus, ascending central cholinergic nuclei and
____
monoaminergic nuciei (23, 24).
EphA6 In the neonatal mouse: the fleurons of the cochlear/spiral ganglion in the
inner ear and whole brain (25). In the adult mouse: the thyrnocyte (7).
In the embryonic rat: ail over the body and head. In the postnatal and adult
rat: only in the brain (23).
In human: high in the testis; moderate in the brain and colon; low in the
kidney, thymus, heart, lung, pancreas, small intestine, bladder, utems,
prostate and bone marrow (10).
EphA7 In the embryonic and postnatal mouse: predominantly in brain at embryo
stage, also in various organs outside the nervous system during development:
kidney, iung, limb buds, and to a lesser degree in the heart, liver, gut, and
genital tubercle (26, 27). In the adult mouse: the brain, testes and, at lesser
intensity, spleen (26), and thymus (7).
In rat: strong expression from fetus to adulthood, especially in the brain, and
may also in the retina and heart (28, 27, 29).
In human: the brain, heart, kidney, and lung (20); high in the kidney, bladder,
brain and testis; moderate in the spleen, small intestine, uterus and prostate;
Iow in the lung, thymus and bone marrow (10).
EphA$ In the adult rat: the brain (30) and thymus (7).
In human: high in the testis and moderate in the brain (10).
EphBl In the embryonic mouse: the brain, cerebellum, and spinal cord during
development; In the adult mouse: the hippocampus and cerebellum (14).
In the embryonic rat: high levels in the cerebellum, brainstem, diencephalon,
and caudate nucleus (31).
In human: high in the brain and testis; moderate in the colon and kidney; low
in the thymus, heart, tung, pancreas, small intestine, spleen, bladder, uterus
and prostate (10).
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EphB2 In the fetal mouse: the neurocctoderm (32), ventral midbrain, ventroposterior
forcbrain, ventral neural tube, the developing dorsal root ganglia, hindbrain,
retina, posterior haif ofthe foregut pocket, mesoderm around the heart (13),
mesenchyme and heart (33).
In the fetal rat: high in the brain cortex, modest in ah fieÏds of the
hippocampus, and in a subset of Purkinje ceils of the cerebellum, weakly in
Schwann cells (17).
In human: the lung, thyroid, placenta and muscle (21, 30); high in the colon
and small intestine; low in the brain, thymus, heart, lung, spleen, pancreas,
kidney, bladder, uterus, testis, prostate (10, 21).
EphB3 In the embryonic mouse: cerebehlum, Purkinje cells, hippocampus (17), head
mesenchyme, developing somites, foregut, first and second branchial arches,
lateral rnesoderm of the forelimb bud (13), venous endothelial cells, and
some arteries (33). In the adult mouse: the brain, liver, lung, kidney, intestine,
testes, placenta, muscle, and heart (34).
In human: high in the coton, brain and lung; moderate in the uterus, prostate,
small intestine, kidney and bladder; low in the thymus, spleen, testis and bone
marrow (10).
EphB4 In the ernbryonic mouse: the epithehial lining of the brain and ventricles,
thymus, lungs, heart, spleen, the entire glomeruli of kidney (34), and ah
major veins (33). In the adult mouse: brain, heart, lung, kidney, placenta,
testes and muscle (35)
In human: the fetal heart, lung, liver, and kidney, lesser signal in brain; aduit
placenta and pancreas (36); high in the lung; moderate in the spleen, liver,
testis, uterus, kidney, bladder, colon (10); low in the skeletal muscle, heart
(36), prostate, small intestine, thymus, and bone marrow (10).
EphB5 No documented data in rodent and human tissue.
In the chicken: the thymus (37).
EphB6 In the aduit mouse: high levels in the thymus and brain (3$).
In human: high levels in the thymus, moderate in the brain and testis, low in
the lung, spleen, uterus, prostate, smahl intestine, kidney, bladder, colon and
bone marrow (10).
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUANG YU 6
EFNA1 In the fetal mouse: the lung, the epithelium of the gut, the ossifying bones of
the face, salivary gland, central nervous system and low level in the
connective tissue of septae in the thymus (39); the primitive streak, lateral
mesoderm, tailbud, and at lower levels in the blood vessels (40); In the aduit:
the thymocyte (7).
In the embryonic rat: the epithelial ceils and the endothelial cells in lung,
kidney, intestine, skin, skeletal system, teeth, heart (endocardium), and dorsal
root ganglia neurons (41). In the postnatal rat: high levels in the lung, low
levels scattered throughout the thymus (39).
In human: high in the lung, colon and liver; moderate in the bladder, kidney,
prostate and uterus; low in the brain, thymus, spleen, srnall intestine and testis
(10).
EFNA2 In the embryonic mouse: high levels in the midbrain and lower levels in the
dorsal anterior hindbrain; outside the nervous system, in the lst and 2nd
branchial arches, somites, and limb buds (16, 40).
In postnatal mouse: the hippocampus in a lateral to medial gradient, and an
increasing gradient from dorsal to ventral septum (22); the thymocytes (7).
In human: high in the colon; moderate in the bladder, small intestine and
liver; low in the brain, kidney and testis (10).
EFNA3 In embryonic mouse and rat: almost exclusively in the central nervous system
besides the skin (42). In the aduit mouse: thymocyte (7).
In human: high in the brain; moderate in the colon; low in the thymus, lung,
liver, bladder, kidney, prostate, utems, small intestine and testis (10).
EFNA4 In the early embryonic mouse: the ectoderm of branchial arches, the forelimb
bud, the anterior spinal cord, and throughout each sornite the limb over the
proximal Iirnb and hand/foot plate (40); In the aduit: thymocytes (7).
In the embiyo rat: the forebrain, olfactory bulb, hippocampus and cortex; In
the adult: low level in the brain (31).
In the human fetus: the heart, lung, and kidney offetus; In the aduit: high in
the colon; moderate in the lung, kidney, bladder, small intestine and prostate;
low in the thymus, utems, liver, spleen, testis and boue rnarrow (10).
EfNA5 In mouse: the brain, heart, intestine, kidney, and at lower levels in the lung,
liver (43) and thymocyte (7).
In human: the heart and placenta (44); high in brain and kidney; moderate in
the lung, spleen, bladder, colon and testis; low in the thymus, liver, prostate,
utems and small intestine (10).
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EfNB1 In the embryonic mouse and rat: high level in brain, sciatic nerve (42) and
kidney; moderate in the heart, lung, skeletal muscle and thymus; low in the
liver (42, 45).
In the aduit human: high in the bladder, lung and colon; moderate in the
kidney, spleen, small intestine, uterus and testis; low in the brain, liver,
prostate and thymus (10).
EFNB2 In the fetal mouse: the hindbrain, branchial arches, in two intense regions of
new somite formation, and a weaker signal in the forebrain (46).
In the fetal hurnan: the heart, lung, kidney and brain.
In the adult human: high level in lung, kidney (47, 48) and colon (10);
moderate in the brain, kidney, small intestine, testis and bladder; low in the
thymus, spleen, liver, prostate and uterus (10).
EfNB3 In the mouse embryo: high level in the brain, lower levels in the heart, lung,
and kidney.
In the aduit mouse: high levels in various sites ofthe central nervous system,
and also in the heart (49).
In the aduit hurnan: high in the brain; moderate in the utems; low in the
thymus, liver, kidney, small intestine, testis, bladder, prostate, lung and colon
(10).
The expression of some Eph and EFN members in immunological compartments bas been
reported during the past years. Hek (EphA3) protein was detected in a pre-B ceil acute
lymphoblastic leukemia cdl une (LK63) in early 1992 (50), and later on, in chicken embiyo
thymus (37). Following that, several other Eph and EFN members were found in mice, rat
and hurnan lymphoid cells or immune organs (6, 7, 9, 14, 15, 20, 26, 38, 42, 45, 47,48, 51, 52,
53). However, the majority of these informations were derived from the detection at the
mRNA level, and sorne contradictory resuits were reported. For example, EFNA1, A3 and
AS were undetectable in thymocytes in early studies (54), but were later found to be
expressed in these cells (7). Such a discrepancy may 5e due to the sensitivity ofthe different
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assays employed. In the last three years, more and more Eph members and their ligands have
been detected in the immune system (7, 9, 10). A general expression profile ofEph and EFN
members in major immunological compartments is summarized in Table 2.
Table 2. The expression of Eph and EfN members in murine or human immune system
EphI EfN Spleen thymus Reference
EphAl + ++ 6, 9, 10
EphA2 + / ++ + /++ 15, 9, 10
EphA3 + + 7,9,10
EphA4 + + 21,9, 10
EphA5
EphA6 + 10
EphA7 ++ + 26, 10
EphA$ + 7
EphA9
EFNA1 + + 39, 10
EFNA2 + 10
EfNA3 + + 7
EfNA4 + + 7
EFNA5 ++ + 7,10
EFNA6
EphBl + 10
EphB2 + + 30,21, 10
EphB3 + + 10
EphB4 + ++ 34, 36, 10
EphB5
EphB6 + +++ 38, 10
EfNB1 +/++ + 42,55, 10
EFNB2 +/++ + 47,48, 10
EFNB3 + + 10
There are variations in the distribution and expression levels in different species, tissues and
developing stages. Pattems shown are for embryo or aduit ofmice, rat or human. The +++,
++, + represent strong, moderate, weak expression.
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1.1.2. The structure of and interaction between EFNs and Eph receptors
The Eph receptors are type I transmembrane proteins (56) (Fig. 1 A). The extracellular
sequence lias an N-terminal ligand-binding domain, a cysteine-rich domain and two
fibronectin type III domains. In the cytoplasmic sequence, alrnost ail the Eph members have
a juxtarnembrane segment, a highly conserved tyrosine kinase domain (57, 58), a sterile u
motif (SAM), and a C-terminal PDZ-binding motif The cysteine-rich region close to the
ligand-binding domain is believed to be involved in receptor—receptor interactions (59). The
biological function ofthe two fibronectin repeats is not clear so far, but they possibly interact
with other proteins (60). The SAM domain may have a role in receptor dimerization (61) or
oligomerization (62), and it may also interact with adapter proteins (4).
Ail EFNs share a basic structural component, i.e., a unique conserved extracellular
receptor-binding domain at the N-terminus. In the EFNB subclass, an additional highly
conserved cytoplasmic domain and a C-terminal PDZ-binding motif are also found, and
these are believed to be involved in protein-protein interactions that mediate membrane
localization and reverse signaling (63). The EfNA subctass members have no
transmembrane region, and they are linked to the celi by a glycosylphosphatidylinositol (GPI)
linker (Fig. 1 B).
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fig.1. The structure ofEph and EFN
A. The Structure of Eph. B. The Structure of ephrinA and ephrinB. Abbreviations: GPI,
glycosylphosphatidylinositol; SAM, sterile-Œ-motif; PDZ, PSD95/Dlg/ZO 1 -binding motif.
The consequence of EFN and Eph interaction is the initiation of the signaling events in the
receptor bearing celis (forward signaling), or signaling into the ligand bearing ceils (reverse
signaling). It is also possible that the forward and reverse signaling, occur at the same time
(bidirectional signaling).
The Eph-EFN-mediated signaling depends on the association of Eph receptors and Iigands.
When Eph and EFN meet, there is initial conformational change in both the receptors and
ligands to achieve a better fit for the receptor-ligand interaction. Receptors and ligand
oligomerization, i.e., trimers composed oftwo receptors and one ligand, or tetrarner oftwo
Ligand binding dornain
Cysteineiich domain
Juxtamembrane dom ain
Kinase dom ain
SAM
PDZ
Eph
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receptors and two ligands, is basically needed to trigger forward and /or reverse signaling
(64).
The interaction between Eph and EFN is prorniscuous, and recent evidences underline this
characterisfic. In general, as illustrated in Fig.2, the EphAs interact with EFNAs, and the
EphEs interact with EFNBs. However, sorne exceptions exist. For example, in addition to
binding to ail ofthe five EFNA subclass members, EphA4 can also bind to EFNB2 (49, 65).
Most recently, EphB2 and EFNA5 were shown to be able to bind one another with high
affinity (66). This further complicates the existing profile of receptor-ligand interaction
between different Eph and EFN members.
fig.2. Interactions between Ephs and EFNs
Solid unes represent the proven interactions between the receptors and ligands. Dashed unes
indicate possible interactions. (Data corne from: 65, 5, 54, 67, 68, 7, 69, 70, 66)
qii.in
EFN1 EFHA
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In addition to the prorniscuity, another characteristic ofthe Eph ligand-receptor interaction is
that ligands and receptors need to be membrane-bound to be effective in triggering forward
or reverse signaling. The soluble forms are not only inactive, but can be antagonistic to the
membrane-bound ligands or receptors (42, 44, 71). Such a characteristic constitutes the basis
for the requirement of direct contact between Eph and EfN-bearing ceils to initiate the
biological function of Eph and /or EFN.
1.1.3. Function ofEFN and Eph receptors
Eph and EfN have been implicated in the regulation of many critical events during
development, and to some extent in aduit life.
So far, the best-defined biological function of Eph and EfNs is the mutual ‘repulsive” or
“attractive” effects on ceils expressing Eph and EFN, such effects resulting in structural
modulation in tissue morphology, such as axon guidance (72), vascular development (73),
and celi migration (74).
The roles that Eph and EfN may play in adulthood are related to angiogenesis (75)
carcinogenesis (76 ), turnor metastasis (77), and T ceil regulation (78, 53, 9, 7, 79, 80).
1.1.3.1 Eph/EFN in the development ofthe nervous system
One of the most important functions of Eph-EFN interaction is their involvernent in axon
guidance or pathfinding. Both Ephs and EFNs are expressed on axons and ceils of neural
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origin and their expression may follow a specific space and time pattem. During
developrnent or structural reformation ofthe nervous system, the Eph and EFN bearing ceils
receive signais from each other and thus rnodify their growth pattem. Although the effect of
Eph!EfN interaction may also be pro-adhesive (81), the majority of evidence showed that
such a signal is repulsive. for example, EphA3 expression follows gradient in the tectum and
retina. When EfNA2, a ligand of EphA3, is overexpressed in the compiementary region of
Eph expression, the axons tum to an abnormai direction (82, $3, $4, 85). Such a repulsive
function ïs also supported by observations from mice with mutations of some Eph members
(86, 87, 8$).
The importance of Eph receptors and EFNs in the aduit has drawn attention in recent years.
Significant expression of some Eph and EFN members lias been found in the aduit nervous
system (10), and a role for EphB in the reguiation of neurai stem ce!! migration has been
described (4). How important Eph-EfN interaction is in the regulation of the aduit nervous
system needs to be further eiucidated.
1.1.3.2 Eph/EFN in angiogenesis
In addition to their ftinction in the nervous system, Eph receptors and EfN Iigands are also
involved in other morphogenic events, such as angiogenesis. Several Eph and EFN members
play a critical role in normal vascular formation. for example, EfNA1 and EphA2 are highly
angiogenic ($9), although the effect is not solely caused by the Eph-EfN interaction, and
may depend on the contribution from other moiecules (90). Some EphB and EfNB subc!ass
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members, sucli as EphB4 and EFNB2, also participate in the development of the
cardiovascular system (33, 91, 73, 92). The pivotai roles of Eph and EFN members in
angiogenesis have been dernonstrated both in vitro and in vivo, and this topic is reviewed in
detail by Brantley-Sieders et al. (93). In accordance witli the observation ofthe formation of
topographie projection maps in the neiwous system (81), Eph/EFN interaction can generate
both positive and negative bioiogical effects on angiogenic celis, to promote
neovascularization (74), regulate arteriovenous differentiation and controi vascular
horneostasis (94).
1.1.3.3 Eph/EFN in tumor tissue
Mutation andlor over-expression of receptor tyrosine kinases have been shown to be
associated with turnorigenesis a decade ago (95). The Eph famiÏy lias been known to be
related to cancers since the first member, EphAl, was discovered (1). Severai Eph family
receptors are found in turnor tissues or turnor-derived celi unes. For exampie, EphAl is
over-expressed in various tumors, including breast, iung, iiver, colon, and prostate
carcinomas (1, 8, 96); some other EphA and B members, including EphA2, A3, A4, 82, 33
and 34, are also over-expressed in tumor ceil unes (50, 97, 9$, 35, 99, 100).
The Eph expression levels seem to be related to the rnalignancy of tumors. Some Eph
members are detected in the undifferentiated and invasive mammary tumors, but flot in
well-differentiated and non-metastatic tumors (35). However, a comprehensive investigation
on cells derived from normal tissues, and non-invasive and invasive tumors, respectively,
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shows diverse EphIEfN expression profiles. Upregulation of some Eph and EFN members
are positively related to tumorigenesis andlor invasiveness, while some other members are
downregulated (101).
Although over-expression of EphAl in mouse NIH 3T3 fibroblast ceils induces colony
formation in soft agar and tumor formation in nude mice (102), few data are available on the
causal effect of Eph/EFN on tumorigenesis. Recent data support a model in which Eph-EFN
interaction prornotes tumor growth by stimulating angiogenesis (103).
Thus, although a growing body of evidence supports the involvement of EfNs and Eph
molecuies in tumor angiogenesis, the data are flot sufficient to prove a causal effect of Eph
and EFN in inducing cell transformation. On the other hand, Eph and EfN are quite possibly
involved in the metastatic phase of cancers and the angiogenesis of tumor tissues.
1.1.3.4 EphIEFN in the immune system
The expression of some of the Eph kinases and their ligands on immune cells has been
documented (Table 1 and 2). However, the function of this largest RTK family in immune
responses was basically unknown until we started our project in 2001. We have reported that
a kinase defective Eph family member, EphB6, is capable oftransducing signais into T cells
(104). Activation ofEphB6 with solid phase anti-EphB6 mAb results in Jurkat cell apoptosis.
Later on, we found that EphB6 can augment normal human T-cell response to Ag stimulation
(53). However, probably due to overlapping functions of Eph kinases, no abnormal
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phenotype in terms of thymocyte structure and subpopulation composition is found in
EphB6’ mice (105). It is to be noted that no detailed study on the functional defects in the
EphB6 immune system was conducted in that study. In the same year, Munoz et al. reported
that a few soluble recombinant EphAs and EFNAs interfere with T-cell development in
thymie organ culture (9), and Sharfe et al. described that several EFNs, notably EFNA1,
inhibit T-cell chemotaxis (7$). Recently, Roifman’s group (80) showed that EphB6 can
influence T cell immune response by downregulating anti-CD3-induced IL-2 secretion and
CD25 expression in a ligand-dependent manner. When murine thymocytes are stimulated
with EFNB 1, TCR-mediated apoptosis is inhibited, suggesting that EphB6 may be involved
in thymocyte development during positive or negative selection.
In addition to the resuits mentioned above, in situ hybridization revealed strong EfNB Ï, B2
and 33 mRNA signals in the cortex ofthe thymus and white pulp in the spleen (106, 107, 10$,
109). Taken together, the data raise the possibiiity that EFNBs might play pivotai roles in
regulating T-cell development and function.
1.1.4. Signaling by EFN and Epli receptors
Although activation of Eph receptors may follow some general rules estabiished for other
RTKs, the signal transduction by the Eph receptors and EFN ligands has a number of unique
features. The EFN ligands need to be membrane-bound to be effective, and misregulated
tyrosine kinase activities of many Eph members are flot oncogenic in contrast to other
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receptor tyrosine kinases. It is also unusual that the Eph-EFN signaling is bi-directional, i.e.,
both receptors and ligands can transmit signais into ceils.
1.1.4.1. Forward signaling by Eph receptors
The exact process ofEph-EfN interaction is flot well understood for each receptor and ligand
member. The crystal structure analysis on some Eph/EfN members revealed some dues in
recent years (61, 110, 111, 112). Before ligand binding, the kinase domain in Eph sticks to the
juxtamembrane segment, on an autoinhibited conformation. Upon ligand binding,
juxtamembrane tyrosines of Eph can be phosphorylated; this releases the autoinhibition and
free phosphotyrosine sites for SF12 domains-bearing signaling proteins (11 1). In addition to
such a de-autoinhibition rnechanism, some phosphoiylation-independent interactions
between EphB and substrate proteins also exist (113).
Many SH2-domain-bearing adapter proteins are involved in the Eph signaling. for example,
Grb2, Grb7 and GrblO bind to EphBl (114, 115); Abi and Arg bind to EphB2 (113). Through
their SF12 binding domains, the adapter proteins, such as Shc and Nck, can interact with Eph
receptors and influence the activation of the JNK or ERK pathway (116, 117). The
recmitrnent of Shc may resuit in tyrosine phosphorylation, which provides binding sites for
the SH2 domains on other adapter proteins. Nck can interact with downstream effectors, such
as Pak3 and WASP (72, 118). Notably, AbI and Arg may interact with Eph through their C
terminal tails other than the SF12 domains (113).
Some small GTPases of the Rho family (Rho, Rac and Cdc42) are involved in Eph receptor
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signaling (78, 119, 120). Examples corne from both Eph A and B subfamilies, although there
are sorne differences between these two groups. Stimulation of EphA receptors can activate
Rho GTPases (119), and downregulate the activation ofRac (120) and Cdc42 (7$). On the
other hand, EphB can influence the intersectin-Cdc42-WASP-actin pathway (121), or induce
transiocation ofRho-GEF kalirin to the site where other target signaling molecules exist, and
further activate downstream targets, such as small GTP binding protein Rad (ras-related C3
botulinum toxin substrate 1, rho family) (122).
Ligation of EphB receptors with EFNB Iigands can also activate Rapi (123, 124, 125), a R
Ras-like protein that positively modulates integrin-rnediated adhesion (126, 127). Such
activation may be mediated by some other adaptor proteins (128), such as Crk (123).
The Src non-receptor kinases may also be related to Eph signaling (129). Some Src proteins
can be activated afler Eph ligation, and the Src family kinase fyn is important to Eph
signaling in modification of ccli adhesion (130, 131).
Recently evidences have shown that Eph/EfN5 signaling interferes with some growth factors,
e.g., vascular endothelial growth factor (VEGF) (90). The effect of EphA and EfNA on
angiogenesis is achieved with the involvement of VEGF, and phosphoinositide 3-kinase
(PI3K) and Rad GTPase arc aiso related to such an activity (132). EphA ligation may inhibit
proliferation ofprostatic epithelial ceils and endothelial cells through downregulation ofthe
Ras/MAPK cascade (133, 134), which is activated by some growth factors, e.g., epidermal
growth factor (EGf) and VEGf. However, such signaling events are not universai. for
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instance, EfNA1 inhibits proliferation in prostatic epithelial celis and endothelial ceils, but
flot fibroblasts (133).
Our laboratory is the first one who discovered that the Cbl is invotvcd in Eph signaling in T
celis (104, 135, 136, 137). EphB6 cross-linking by Ah in Jurkat celis causes Cbl
dephosphorylation (104). CbI phosphoiylation is observed in both Jurkat ceils and peripheral
blood T celis stimulated by EFNA1 (79); such EphA activation-induced Cbl phosphoiylation
may employ adapter protein Crk-L and Crk-II, with an involvement of Src family kinases.
However, stimulation of EphB receptors with EfNB Ï does not induce Cbl phosphorylation
in Jurkat cells (79). Recently, Roifman’s group demonstrated that EFNA1 stimulation of
Jurkat celis could cause down-regulation and degradation of endogenous EphA3 receptors.
EphA receptor expression is down-regulated in ceils overexpressing of wild-type Chi,
suggesting that CbI rnight be a negative regulator of Eph receptors ($0). In addition, they
found that TCR-mediated activation of the JNK pathway is selectively inhibitcd upon
stimulating overexpressed EphB6 with EFNB 1. According to their speculation, srnall
GTPase Rad is possibly involved in this event.
So far, although the repertoire ofrnolecules involved in Eph fonvard signaling is expanding,
the available information is insufficient to develop a complete architecture of these Epli
signaling pathways.
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1.1.4.2. Reverse signaling by EFN ligands
Although the existence of EFN reverse signaling has been obsewed for almost ten years
(138), and the reverse signaling is one of the critical feature of Eph-EfN interaction (139,
140, 92), the mechanisrn of reverse signaling stili Yacks details.
Several evidences suggest that EFNB-induced reverse signaling is mediated by proteins
bearing SH2 domains (141, 142, 143), and that Src family kinases (SFK5) is responsible for
EFNB phosphorylation upon Eph receptor engagement (144, 145). In the EFNB-expressing
ceils, ligation with EphB causes rapid recmitment of SFKs, and induces transient SfK
activation, which is possibly mediated by phosphorylation of the tyrosine residues and the
engagement with PDZ domain proteins (145). Other PDZ-bearing proteins, such as RGS3,
and SH2-bearing molecules, e.g., Grb4, can also induce the reverse signaling upon EFNBs
receptor ligation (142, 146, 63). RGS3 can further regulate downstream G protein signaling.
Grb4 can link EfNBs to a number of signaling molecules, such as the Cbl-associated protein,
the Abl-interacting protein-1, dynamin, PAK1, and axin (63). Activation ofEFNB1 increases
fak activity, redistributes the fak-binding protein paxillin, and leads to disassembling of
focal adhesions (63, 123).
EFNA can also induce reverse signaling. Some evidences demonstrate that EFNA can recruit
the Src family kinase Fyn to lipid rafts upon Eph ligation. As a consequence, tyrosine
phosphorylation of a 120 kD lipid raft protein and activation of MAP kinases are observed
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(147, 148); however, the mechanism is unclear.
1.2. T-ceIl development in the thymus
The thymus is the cradie of T celis, and is a complex prirnary iymphoid organ composed of
stromal ceils and immigrant hemopoietic celis. Anatomically, the thymus can be divided into
three regions: the subcapsuie region, the cortex, and the medulla (9). Hemopoietic stem celis
enter the thymus and go through the early stage of developrnent within the subcapsule and
cortex where they iose the abiiity of differentiating to non-T ccli lineages, and are graduaily
comrnitted to the T-celi lineage (149).
At the eariiest stage in the murine thymus, the lymphoid precursors are characterized as
CD4’°CD8CD25CD44c-Kit (150). Between 12.5 and 14.5 of embryonic days
(E12.5’-E14.5), lymphoid precursors differentiate to the T-cell lineage; the thymic epitheliai
ceils are flot abie to sufficiently support T-ceii developrnent at the stage earlier than E 12.5
(151). Sorne celi surface markers, such as CD25, CD44, CD117 (c-kit) and CD127 are
considered to be indicators of T-ce!! lineage commitment (152, 153), and the Notch signaling
is believed to play a pivotai role to the commitment (154). At this stage, CD3 CD4 CD8 are
negative in the T ce!! precursors; so these celis are often named TN celis. These TN can be
further classified into TN1 (CD44CD25CD117CD127), TN2
(CD44CD25CD117CD127), and TN3 (CD4410CD25+CD117I0CD127E0). The TN2 ceils
upregulate the expression ofpre-TCR (pT) gene and begin to rearrange the TCR gene (152,
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153). Then, along with further TCR gene rearrangement, the TN3 ceils definitely commit to
the T-cell lineage. These celis wifl tum to be CD4+CD8+CD3b0t, also called double positive
(DP) celis (155).
The DP ceils then undergo extensive positive and negative setections, and differentiate into
mature CD4 or CD8 single positive T ceils that express higb leveis of CD3-associtaed TCR,
and are ready to move out of the thymus as functionai and self tolerant mature T celis.
1.2.1. Positive selection
Positive selection refers to a process that choose the developing DP celis capable of
recognizing self-MHC (maj or histocornpatibility complex) molecules for further
differentiation and survival (156, 157).
The positive selection requires the contact between TCR on the DP thymocytes and the
MHC-peptide complex provided by other celis (158, 156, 159); the majority of MHC for
efficient contact is suppiied by thymic stromal celis at the subcapsuie and cortex region (160).
Both the concentration and specificity of antigenic peptides prcsented by MHC are important
in determining the strength ofthe TCR signaling, and thus the fate ofthe DP cells (158, 161,
162, 163, 164, 165). Obviously, the molecules that can regutate TCR signaling, such as
CD8O (166), Cbl (167) and LAT (168), may influence the outcome. Notably, it seems that the
cortical epithelium expresses some unique moiecules that may provide additional signais
required during the positive selection (156, 163).
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUANG ‘u 23
The thyrnocytes that pass through the positive selection will further develop into CD4CD8
or CD4 CD8 single-positive (SP) thyrnocytes. Those who recognize class I MHC develop
into CD8 cytotoxic T lymphocytes (CTLs), and the others who interact with class II MHC
commit to helper CD4 cells (169, 170, 171).
1.2.2. Negative selection
Negative selection is a process to delete the maturing D? celis capable of recognizing self
MHC-peptide complex with high affinity. This is a critical mechanism to keep the mature T
ceils from being reactive to self-Ag.
Negative selection of thymocytes takes place either in the cortex at the cortex-medulla
junction or within the thymic medulla (172, 173); it occurs probably not earlier than the
CD4I0wCD8I0w TCRII1ÉCD69± stage (174). Dendritic cells (DC) play an important role for this
process (175). Some accessory molecules, which can influence TCR signaling, such as
CD4O/CD4OL and CD28, also play important roles in negative selection (174, 176).
However, their involvement appears flot just as simple as co-stimulation or modulation of
TCR signaling. For example, Fas (174) and LIGHT (177) are able to affect negative selection,
but FasL does not have obvious effect (174), suggesting the existence of a more complex
mechanism than that ernployed in the mature T cells.
1.3 Co-stimulation in T-celI activation
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The recognition of antigens by specific lymphocyte receptors constitutes a fundamental
irnniune reaction, and T celis are a critical component for an effective immune response
against a wide range of pathogens. Mounting an appropriate T-ce!! response depends on
de!icate regu!ation of lymphocyte activation. To become fu!!y activated, two independent
signais are required. The first is an antigen-specific signal that is de!ivered through theTCR.
The second one is termed co-stimu!ation that works independent!y of TCR. Accumulating
knowledge indicates that co-stimulation plays a crucial role in T-cel! activation (178),
proliferation (179), differentiation to effector (180) or rnemory status (181), anergy (182),
and apoptosis (183).
The co-stimulation mode! (or two-signal theory) of T-ce!! activation was first proposed by
Lafferty and colleagues (184). Many celi surface mo!ecules and cytokines, such as 37(185),
CD44 (186) and 1L2 (187 ) can transmit signaIs to enhance T-cell activation. Accumu!ated
evidence indicates that bidirectional communication between T celis and accessory cel!s
exists, and that this kind of interaction can evoke mutua! stimulation (188). Now it becomes
clear that interactions between responder lymphocytes and “accessoiy” celis represent a
critical event in the T-ceII activation process; such interaction is usually called co-stimulation.
However, there is stiil no general agreement on what exactly defines “co-stirnulation”. The
use of “negative co-stimulation” for inhibitory signaling events further confuses the
terrninology. for the convenience of the discussion here, a co-stimu!atoiy molecule is
defined as an initiator of a positive signal by increasing TCR avidity (for example, adhesion
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moiecuies) or enhancing the recruitrnent of tyrosine kinases to the TCR compiex (for
example, the co-receptor CD4) (188). Those inducing negative signais are flot called co
stimulatory molecules, but are nevertheiess discussed.
1.3.1 Co-stimulatory molecules
The first ce!! surface molecule shown to function as a co-stimuiatory molecule is CD2$ (185).
Since its identification, the number of candidate co-stimulatory molecules has significantly
increased (189, 190).
Most mo!ecules that induce co-stimu!ation can be divided into two classes based on sequence
homology.
The first c!ass is composed of members of the 1g superfami!y, including CD2$ family
members. These molecules share several structural and functional features. Ail of the
CD2$-!ike receptors are type I transmembrane g!ycoproteins (191). The CD28 fami!y
comprises CD2$, CTLA4, ICOS (H4, AILIM) and PD-1; CD28 appears to be the major co
stimuiatoiy molecule for the activation ofnaive T ce!!s. The ICOS mainiy works on activated
or effector T celis. The other two receptors, CTLA-4 and PD- 1, a!though they share structura!
hornoiogy with CD28 and ICOS, appear to be both inhibitoiy in nature. The ligands of the
CD2$ fami!y members be!ong to the B7 fami!y, and these ligands are also members of the 1g
superfami!y.
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The second class of co-stimulatoiy molecules comprises members of the TNf receptor
(TNFR) family, including CD4O, the major B ce!! co-stimu!atory mo!ecu!e, as well as OX-40,
4-1BB, CD27, CD3O, and HVEM (herpes-virus entry mediator). The ligands for these
receptors are membrane-bound members of the TNF family, e.g., 0X40 ligand (OX4OL),
4-ÏBBL, CD7O, CD3OL and LIGHT, respectively. The co-stimu!atory TNFR-family
members are mainly expressed on T celis, and their ligands, on antigen-presenting cel!s (192,
193).
1.3.1.1. The major co-stimulatory molecule CD2$
CD28 is constimtively expressed on the surface of 80% ofhuman T ce!!s (a!! CD4 ce!Is and
about 50% ofCD8 ceils) and on virtually !00% ofmurine T ce!ls (185, !94). Studies in vitro
and in vivo have shown that CD2S is the primary co-stimulatory molecule for naive T celis,
and CD4 ce!!s are more dependent than CD8 ce!ls on CD28 co-stimu!ation in vivo (!95,
196).
The major function of CD28 signaling is to act in concert with TCR stimulation. CD28
!igation can enhance the transcription and stabi!ity of IL-2 mRNA, partially through
cyclosporine insensitive signa!s (197). In recent years, accumulated data reveai more broad
and proxirnal intersection of CD28 signais with those mediated by TCR (198, 199, 200).
Ligation ofCD28 on naive T ce!!s by its ligand B7-1 or B7-2 on APC drasticatly enhances
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the TCR signaling that activates protein tyrosine kinases (PTK5). The activated PTKs in tum
phosphorylate critical scaffold proteins, such as the linker for activation of T celis (LAT) and
the SH2 domain-bearing leukocyte-specific phosphoprotein of 76 kD (SLP-76) (201). Such
events are critical for the further recruitment and activation of other key signaling molecules,
such as phospholipase Cy-1 (PLCyI), growth factor receptor-bound protein 2 (Grb-2), son of
sevenless (SOS), and protein kinase C theta (PKC8) (202, 203, 204, 205, 206, 207). Through
these molecules, the CD28 signaling triggers downstream pathways leading to the activation
of the nuclear factor of activated T ceils (Nf-AT), activator protein-1 (AP-1), and nuclear
factor kappa B (NF-KB) transcription factors (203, 208, 209, 210).
Activation of PI3K is one ofthe controversial issues in CD28 down stream signaling. PI3K is
an intracellular signaling enzyme that regulates a wide range of cellular functions (211). In
T-celI activation, PI3K may tyrosine phosphorylation—dependently associate with the
cytoplasmic tau of CD28, phosphoiylate membrane phospholipids phosphatidylinositol
4,5-bisphosphate (PIP2), and generate phosphatidylinositol-3 ,4,5-triphosphate (PIP3) that
can activate a serial ofdownstream signaling targets. Recently, there are evidences either for
and against an essential role of PI3K in CD2$ signaling (212). By introducing mutant CD28
constructs, which cannot bind PI3K, into CD2$-deficient mice, two groups of researchers
obtained strikingly different resuits. One group (205) reported that CD28 Y189f transgenic
T ceils severely reduce the ability of proliferation and IL-2 secretion at the early stage of
anti-CD3 and anti-CD2S Ab stimulation, although the later responses are intact. On the other
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hand, the IL-2 production is totally lost when the celis are stimulated with PMA and anti
CD28 at any time point. In vivo test further demonstrated that CD28 Y1$9F transgenic
spleen ceils do flot induce acute graft-vs-host reaction. Another group (213) showed that the
CD28 mutant (Y 170 in mouse) is more susceptible to radiation-induced death, but does flot
significantly compromise the ability of IL-2 production, celi proliferation and B ce!! help.
The contradiction might be caused by different mutation points; this suggests that the
performance of CD28 might be binding-site dependent. However, in another separate study,
it was observed that T ce!!s from mice lacking the p85 G subunit of PI3K appear to function
normally (214). As the p85 u subunit is believed to be required for CD28 binding to PI3K,
this observation suggests that PI3K is flot required for CD2$ signaling. Thus, the role of
PI3K in the CD28 co-stimulation pathway remains undetcrmined.
Vav is another important signaling protein that regu!ates AP-1 activation, and plays an
important ro!e in the TCRJCD28-induced stimulation (204). Acting as a guanine-nuc!eotide
exchange factor for Rac and Cdc42, Vav a!!ows these molecu!es to switch from an inactive
GDP-bound state to an active GTP-bound state (215). Signa!s from either CD3 or CD28 can
independently phosphory!ate Vav and activate it, with CD28 being more potent and inducing
more sustained phosphorylation. Vav may provide a link between CD28 and Rac/Cdc42—
controlled events, possib!y through an adapter protein complex composed of SLP-76, LAT,
and Grb2 (216). Vav may receive some CD28 signaIs via PI3K (217), and activate Rac-l, a
ras-like guanosine triphosphatase (GTPase), and induce actin cytoskeletal rearrangement.
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This cytoskeletal change is critical for activation-induced clustering ofTCR and aggregation
ofÏipid microdomains (rafts) that harbour a variety of signaling molecules (199, 200).
In addition to PI3K and Vav, Akt has received attention recently. Akt, also called protein
kinase B or PKB, is a serine/threonine kinase that is recruited to the plasma membrane when
its pleckstrin hornology domain binds to the phospholipid products of PI3K. In a PI3K-
dependent way, Akt can be phosphoiylated by cross-linking CD28 independent of TCR
ligation (218, 219). The activation of Akt is achieved afler its phosphorylation by
phosphoinositide-dependent kinase 1 (PDK1) and other kinases at the membrane (220). The
activated Akt further phosphoiylates downstream targets. Notably, persistent activation of
Akt can stimulate IL-2 production in mature CD28-deficient T cells (219), even though Akt
has no effect on proliferation of CD28-deficient ceils. It seerns that Akt requires cooperative
signaling from other molecules to mediate CD28 signaling. However, what molecules work
downstream ofAkt to induce the CD2$-independent IL-2 production is so far unknown.
Cdc42 is another signaling molecule that is involved in the CD28-mediated signaling
pathway. It plays a role in cytoskeletal rearrangement through the action of the Wiscott
Aldrich syndrome protein (WASP) and augments IL-2 synthesis via MAPK activation (215).
1.3.1.2 Other co-stimulatory molecules related to T-celt activation and differentiation
Although CD28 is a key co-stirnulatory molecule, it does flot account for ail co-stimulatory
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functions in T celis. The existence of CD28-independent pathways has been demonstrated by
convincing evidences derived from CD28 nul! mice (195), and from APCs lacking B7.2 (220,
221). Accumulating evidence suggests that other co-stimulatory molecules can compensate
for the absence of CD28 signaling; ICOS is such an alternative that lias attracted mucli
attention recently. The structure of ICOS is closely related to that of CD28, but there is no
detectable binding ofICOS to B7.1 or 37.2. The ligand for ICOS, named ICOSL, is a novel
B7 family member (190, 222). On naive T celis, ICOS is either absent or expressed at veiy
low levets, while it is upregulated upon stimulation (223). Co-stimulation by ICOS
contributes to the production of effector cytokines IfN-y, TNF- u , IL-4, IL-5, and IL-10, but
much less for IL-2.
Multiple molecules on T ceils, such as CD2 (220), CD5 (221), CD9 (222) and CD44 (186),
have the ability to costimulate T celis. In the presence ofimmobilized submitogenic doses of
anti-CD3, mAbs against these co-stimulatory molecules aIl induce activation ofnaive T cells,
and the proliferation rates determined 2 days after these co-stimulations are comparable to
that induced by anti-CD28. Remarkably, co-stimulation by these molecules induces limited
amounts of IL-2. Regarding the mechanism of such discrepancy, recent reports suggest that
CD28 delivers a signa! different from that derived from the others (227). There are several
examples to support this notion:
1). Analysis ofthe CD28RE (interleukin-2 CD28 response element) ofthe IL-2 promoter
shows specific transcription factor recruitrnent at the CD28RE elernent upon induction by
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B7-1/SEE (227).
2). Although CD58 (LFA-3, ligand of CD2) co-stimulation is able to induce T-ce!!
proliferation as weIl as IFN-y and IL-4 production at similar levels as in celis induced by
B7- 1, IL-2 promoter activity and production of IL-2 are only seen after B7- 1 co-stimulation.
3). Co-stimulation with either B7-1 or CD58 is both able to further enhance ERK-2 activity
and strongly activate the p38 MAPK pathway, but only 37-1 co-stimulation induces high
levels ofJNK-1 activity (227).
Human B7-H3 has been recently identified as a new co-stimulatory member of the B7 family.
It is expressed on GM-CSf-stimulated monocytes and IFN-y—activated dendritic ceils, as
welI as on CD3 T ceils activated with PMA and ionomycin (22$). 37-H3—Ig fusion protein
can co-stimulate proliferation of CD4 and CD8 T celis through another receptor than CD28
and ICOS; the nature ofthis receptor is currently undetermined.
1.3.1.3 The TNF family
Several members ofthe tumor—necrosis factor receptor superfamily can also deliver positive
co-stimulatory signais both during early and late stages after TCR ligation with antigen. f ive
co-stimulation pairs of the TNFR-TNF family members have been weii recognized as
positive reguiators of T ceil responses, i.e., 0X40-OX4OL, 4-1BB-4-1BBL, CD3O-CD3OL,
CD27-CD7O and HVEM-LIGHT (193). Moreover, some members ofthe TNf ligand family,
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such as FasL, CD4OL, TRAIL, TRANCE and LIGHT, can reversely transduce positive co
stimuiatory signais into T cells (229, 230, 231, 232, 233, 234).
Expression of 0X40 (CD134) is restricted to activated T ceils in humansand rodents (235,
236), whiie CD134L are detected on severai kinds of human and murine celis, such as
activated B ceils (237), dendritic ceils (238), and vascuiar endotheliai ceils (239). It was
proposed that 0X40 signais act in a temporal manner after CD28 stimulation, and aliow
effector T celis to survive and continue proiiferating in iater responses (240, 241).
4-1BB (CD137, ILA) is primariiy expressed on activatedCD4 and CD8 T ceiis (241, 242),
as weli as on activated NK ceiis (243), B ceiis, macrophages, dendritic ceiis and eosinophiis
(244). 4—1BBL is expressed on mature DC, andon activated B ceils and macrophages; its
expression can be regulated by LPS, 1g or CD4O (244, 245, 246, 247). Stimulation of4—iBB
induces higher ieveis of CD8 Tccii proiiferation than for CD4, and appears to be critical for
CD8 celi survivai (248, 249).
CD3O is expressed on activated B or T ceiis. Expression of CD3O on T celis is dependent
upon the presence of CD28 co-stirnulatoiy signais or exogenous IL-4 during primary T ccii
activation (250, 251). CD3OL is expressedon T and B celis, macrophages, and a variety of
hematopoietic celis and tumors (252, 253). On T ceiis, CD3O is primariiy expressed on
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activated CD8 T celis, while CD3OL is on activated CD4 T cells (254). Both CD30 and
CD3OL can affect ce!! activation and ce!! death (251, 255).
CD27 is constitutive!y expressed on T ceils and this expression is significantly upregulated
by reagents that cross-link TCR or CD3 (256, 257). It functions in T-cell activation, T-cet!
development, and T-ce!!—dependent antibody production by B ce!ls (258, 259). CD27 is
irreversibly lost from a subset of long-term repeatedly stimu!ated T celis, which are likely
memoiy celis (256). The expression of CD27L (CD7O) is found on medul!ary thymic
epithelium and can be rapidly induced on both T and B celis after activation. The specific
interaction of CD27 with its !igand CD7O supports clonai expansion of both antigen
stimu!ated CD4 and CD8 T ce!!s, and enhances the generation of cyto!ytic T celis (260).
As a member ofthe TNF !igand fami!y, LIGHT is constitutive!y expressed on “immature’t
dendritic ce!is and expressed on resting as we!! as activated T ce!!s (234). It binds to three
distinct members of the TNf receptor family, i.e., HVEM, LTI3R and DcR3 (261, 262).
LIGHT provides costimu!ation by triggering HVEM on T ceils; such co-stimulation
produces cytokines, including IfN-y and GM-C$F, that are pivotai for Thi type (1-helper
ce!! type 1) immune responses, whi!e IL-4 production is s!ight!y increased (261, 263, 264).
On the other hand, LIGHT itself can reccive co-stimulatory signais and deliver “reverse
signaling” to the LIGHT-bearing T ce!!s (234, 265).
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1.3.2 Inhibïtory molecules
Inhibitory molecules play important roles in the regulation of TCR stimulation. It is the
harmony of co-stimuiatory and inhibitory signais that modulate the eventual magnitude and
quality of immune responses.
The best-studied inhibitory receptor is CTLA-4 (cytotoxic T lymphocyte antigen-4, also
called CD152), a member ofthe CD2$ farnily. CTLA-4 binds to 37.1 and B7.2 with higher
affinity then CD2$. Resting T celis express iittie surface CTLA-4, whose expression
increases upon T-ceil activation. CTLA-4 inhibits T-cell proliferation and cytokine
production induced by stimulation with anti-CD3 and anti-CD28 or other co-stirnulatory
molecules (197, 266, 267). Recent data suggest that CTLA-4 regulates T-ceii signaling by
attenuating TCR accumulation and rctention within the immunological synapse (26$).
Another inhibitory member of the CD2$ family is PD-1. As with the other CD2$ family
members, its ligands, PD-Ll and PD-L2 are related to the B7 proteins (210, 269). PD-l is
expressed on activated T celis (270); engagement of PD-1 leads to inhibition of 1-ceil
proliferation and cytokine production in response to anti-CD3 and anti-CD28 antibody
stimulation (210, 269).
In sumrnary, there is enormous complexity in the ceil-celi interactions regulating T-cell
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activation. Co-stimulatory receptors can bind to more than one ligand, and vice versa (190,
222); they may work in an synergistic (223) or antagonistic (197) way. Extensive studies lead
to continued discoveries of new members of co-stimulatory and inhibitory molecules. The
current known signaling molecules provide us with dues for further understanding of the
molecular mechanism ofT-cell responses.
1.4. The role of lipid raft in signosome and T-cell signaling
1CR and B celi receptors (3CR) bind to Ag in a highly discriminative and sensitive fashion.
These receptors are complexes cornposed of extracellular ligand binding dornains and
intracytoplasmic tails that are responsible for signal transduction. On the cytoplasmic tails of
these molecules, there are conserved signaling components termed immunoregulatory
tyrosine activation motifs (ITAMs). These components do flot have intrinsic kinase activity,
but the tyrosines within the ITAMs become phosphorylated upon TCR or 3CR crosslinking,
due to association of TCRJBCR with cytoplasmic RTKs. It is becoming clear that TCR/BCR
and their downstream signaling molecules are spacially organized on the ceil membrane, and
Iipid rafis is essential in such organization (271, 272, 273, 274, 275, 276, 277, 278, 279).
Lipid rafts are conserved structures that exist in a variety of ccli types. They are relatively
ordered membrane domains, and constitute of lipid-based platforms floating in the ccli
membrane. Their components sphingolipid and cholesterol are usually used as markers for
their detection.
In resting mature T cells, TCR is excluded from iipid rafis that contain severai key
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components of the TCR signaling pathway, including the Src-family kinase, Lck, and LAT
(170, 280, 281, 282). Upon TCR ligation, the CD3 complex moves into rafts where the
Ç chain of TCR is phosphorylated. A number of T-ce!! signaling molecules, inc!uding the
adapter protein SLP-76 and kinase PKC, are recruited to !ipid rafts following TCR activation
(283, 284). The phosphorilated TCR also associates a portion of CD4 or CD8 in !ipid rafis
where they interact with Lck through specific protein-protein interactions (280, 281).
Notably, the proteins described above may only represent a subset of the raft-associated
proteins, because over 70 different raft-associated proteins have been identified in resting T
ceils by using recent protein identification techniques.
Lipid rafts appear necessary for T ce!! signaling. Structural disruption ofrafts interferes with
the ear!iest steps of T-ce!! activation (282). Mice deficient in acid sphingomyelinase, which
is needed for the formation of !ipid rafis, show defective T-cell signaling (285). In addition,
raft-associated Lck is more catalytica!Iy active than Lck staying outside the rafis (286).
Whether CD28 associates with rafis is controversia!. Mounting evidences indicate that CD28
may enhance TCR sing!ing by augmenting !ipid raft aggregation (287, 199), with the
recruitment and activation of signa!ing components, such as PI3K (!98, 287) and Vav (204,
206, 288), into rafis. However, a recent study on primary human T ce!!s demonstrated that
CD3/CD2$ co-stimulation cannot induce lipid rafts polarization in CD8 ce!ls (289, 290).
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The composition of lipid rafts appears different in different ccli populations. Compared with
CD4, CD$ T ceils express higlier levels of a microdomain component, glycosphingolipid
GM 1, and have more Thy- Ï (a ceil surface protein) associated with lipid rafts. In addition,
during the aging process, GM1 levels in CD8 T celis increase (291). Such differences may
be the molecular basis ofthe functional difference between CD4 and CD8 ceils.
The raft also shows difference between naïve and effector T celis. GMÏ resides in
intracellular membranes in the resting celis. The effector celis have very high levels of
plasma membrane-associated GM1 (292).
Lipid rafts are aiso structurally unique in different stages ofthymocyte deveiopment and may
piay an essential role in the positive selection of immature T cells in the thymus. The flrst
rearranged chains of TCR are expressed on the surface of pre-T celis, and signais through
such TCR are important for ccii survival. In contrast to mature TCR that is exciuded from
rafts, a large number of pre-TCRs reside in lipid rafts (293, 294). The persistent presence of
pre-TCR in iipid rafts during the positive selection stage might promote prc-T ccli survival.
At the stage of negative seiection, pre-TCR5 of immature T ceils stay out of the rafts, and
pre-TCR tigation cannot induce stable association betwccn pre-TCR and rafts (290, 295);
this further suggests that iipid raft may piay a criticai role in regulating thymocyte
development.
1.5. The objectives ofthis study
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Although soi-ne members of the Eph and EfN families are expressed in lymphoid organs and
on some leukocytes (Table 2 and 35, 34, 38, 6, 9, 21, 53, 52, 20, 296, 297, 298, 104, 39, 42,
80), we are at the very beginning of understanding the roles of this large family of receptor
tyrosine kinases and their ligands in immune regulation. We have previously reported that
EphB6 crosslinking by mAb leads to signal transduction and apoptosis of Jurkat T cells
(104), as well as augmentation of normal human T-cell responses (53). The objectives ofthis
study are to discover the roles and mechanisms of EfNB family members in T-ceII
developrnent, activation and function.
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ABSTRACT
Eph kinases form the largest family of receptor tyrosine kinases, and their ligands are ephrins
(EFNs), which are ceil surface proteins. Some Eph kinases and EfNs are expressed on T ceils,
B celis, and dendritic celis, but their functions in the immune system are largely unknown. In
this study, we investigated the effect of EfNB2 on murine T ceils. EFNB2 mRNA was
expressed in the cortex ofthe thymus and white pulp ofthe spleen. At the protein level, it was
expressed on T celis and monocytes/macrophages, but flot on B celis. EFNB2Rs were
expressed mainly on T celis. Solid-phase EfNB2 along with suboptimal anti-CD3 strongly
stimulated T celi proliferation, with concomitant augmentation of IFN-y but not IL-2 or IL-
4 secretion. The activity of cytotoxic T celis was also significantly enhanced in the presence
of solid-phase EFNB2. These resuits indicate that EFNB2R cross-linking results in
costimulation of T celis. EFNB2Rs were normally scattered on the T celi surface; after TCR
cross-linking, they rapidly congregated to capped TCR complexes and then to patched rafts.
This provides a morphological base for EFNB2Rs to participate in T cell costimulation. We
also demonstrated that EFNB2R signaling led to augmented p38 and p44742 mitogen
activated protein kinase activation. Our study shows that EFNB2 plays important roles in
immune regulation.
Key words: EphrinB2, Eph kinases, T cells, costimulation
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INTRODUCTION
The Eph farnily of receptor tyrosine kinases (RTK) is the largest arnong the RTK farnilies,
comprising 25% ofknown RTKs (1). According to sequence homoiogy, Eph family members
are divided into EphAs (EphAl to 9) and EphBs (EphBl to 6) (1)
(http://cbweb.med.harvard. edu/eph-nomenclature/cell_iettcr.html). Their ligands are ccli
surface molecules called ephrins (EFNs) (1). EfNs are cÏassified into two subfamilies. There
are six members in the EfNA subfamily (EFNAY to 6), and they are GPI-anchored ccli
surface proteins (1, 2) (http://cbweb.med.harvard.edu/eph-nomenclature/cell_ietter.htrnl).
The EFNB subfamily consists of three members (EFNB 1 to 3), and they are transmembrane
proteins (1, 2). Although they are iigands, EfNs, especialiy EfNB subfamiiy members, can
reverse transduce signais into cells (2, 3). The interaction between Ephs and EFNs is flot very
strict: one Eph can bind to several different EfNs and vice versa. However, in general,
EphAs only interact with EfNAs, and EphBs, with EFNBs (2, 3). Human genome sequences
have rcvealed 14 Eph entries and $ EFN entries (4). Therefore, most of the Ephs and thcir
ligand EFNs probably have already been identified.
Because both Eph receptor kinases and their ligands are ccli surface molecuies, they can
interact only with each other if expressed on adjacent ceils. Not surprisingly, these receptors
and ligands are known to control accurate spatial patterning and ccli positioning. Many of
these findings are derived from studies in the CNS, where rnost Eph kinases have high-Ievel
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expression (3, 5, 6, 7, 8, 9). It lias also been found that EFNB2 and its receptor EphB4 are
involved in angiogenesis (10), and such a function is consistent with the known roles ofEph
kinases in controiling spatial structure formation.
The expression of some Ephs and EfNs in immune celis has been documented. for example,
EphAl (11), EphA2 (12), EphA3, EphA4 (13), EphB2 (14), EphB4 (15), andEphB6(16)are
expressed in the thymus; EphB6 is expressed on mature T ceils (17, 18); EphA3 is expressed
in pre-B ce!! unes (11), and EphA4 and EphA7 are significantly expressed in B celis (19);
EphA2 (19) and EphBl (20) are expressed in certain types ofdendritic ceils; and some Ephs,
such as EphA3 (21), EphB4 (22), and EphB6 (18, 23), are expressed in leukemia ce!ls. As for
EfNs, EfNA! (24), EFNA3, EFNB1 (25), EFNA2, EfNA4, and EfNA5 (13) are expressed
in the thymus; EFNA4 can be detected in peripheral T and B ce!ls (19).
However, we have very hrnited knowledge about the function ofEpli and EFN in the immune
system, and publications in this area are numbered. We have recentiy reported that EphB6,
although it !acks intrinsic tyrosine kinase activity due to a mutation in its kinase domain (16),
is abie to transduce signais into T cel!s, probabiy via adaptor proteins such as Cb!, Grb2, and
CrkL (23), and via EphBl with which it associates (26). EphB6 Jurkat ceiis cross-linked
with anti-EphB6 mAb undergo fas-mediated apoptosis (23). Further detai!ed study showed
that mAb against EphB6 costimu!ates normal human T ce!Is, in ternis of p38 mitogen
activated protein kinase (MAPK) activation, lymphokine secretion, and proliferation (17).
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Initiai exarnination of EphB6 mice shows no gross anomaly in the thymic structure and
thymocyte populations (27), suggesting compensatory mechanisms at work. Munoz et al. (13)
have reported that a few soluble EphAs and EfNAs interfere with T cell development in
thymie organ culture.
In this study, we investigated the immune regulatory role of EFNB2, which is a ligand of
several EphB kinases, including, but flot restricted to, EphB6. The EphBs binding to EfNB2
are collectively termed EFNB2Rs in this study.
MATERIALS AND METHODS
In sitti hybridization
A 656-bp cDNA fragment of mouse EFNB2 cDNA from positions 29 to 684 (accession no.
NMOÏO 111) was fetched with PCR from a mouse embryonic tissue cDNA library and cloned
into pGEM-4Z (Invitrogen, San Diego, CA). The resulting construet pGEM-4Z-m32 was
used to transcribe antisense probes with SP6 RNA polymerase or to transcribe sense probes
with T7 RNA polymerase, using digoxigenin (DIG) RNA labeling kits (Roche Diagnostics,
Lavai, Quebec, Canada). Mouse thymus and spleen were embedded in optimal cutting
temperature compound, sectioned at 7-tm thiekness, and kept at -80°C until tested. The
sections were thawed for 5 min at 55°C and fixed in 4% paraformaldehyde in PBS for 10 min
at 4°C. After rinsing in PBS (pH 7.4) for 2 mm, the sections were immersed in 0.2 N HC1 for
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10 min at room temperature, briefly washed three times in PBS, and digested with 1 ig/m1
proteinase K in 50 mM EDTA and 100 mM Tris (pH 8) at 37°C for 30 min. Proteolysis was
arrested by immersing the siides in 4% paraformaldehyde in PBS for 5 min at 4°C, followed
by three 2-min washes in PBS. After the above pretreatments, the siides were incubated in a
solution containing 50% deionized formamide and 2x SSC (lx SSC: 150 mM NaCI, 15 mM
trisodium citrate (pH 7.0)) at 37°C for 30 min. The siides were exposed to 40—60 jil of
hybridization mixture containing 1.5—3 ng/il DIG-labeled antisense or sense RNA probes in
hybridization buffer (50% deionized forrnamide, 2x SSC, 0.1% SDS), heated at 55°C for 5
mm, and then incubated at 42°C for 16—18 h in a chamber humidified with 50% formamide
in 2x SSC. finally, the siides were washed twice in 4x SSC, once in 2x SSC, and once in lx
SSC for 15 min each. Signais were detected by aikaline phosphatase-conjugated anti-DIG Ab,
with 5-bromo-4-chloro-3-indolyi phosphate as substrate and 4-nitroblue tetrazolium chioride
as chromogen, according to instructions for the use of DIG detection kits (Roche
Diagnostics). The sense probe was taken as a negative control. As additional negative
controis, one siide for each experiment was treated with RNase A before hybridization to
deplete mRNA, one slide was hybridized with omission of the probes, and one siide was
detected with omission of the prirnary Ah during the DIG detection procedure. These
additional negative controls reveaied no signais, and photographs ofthem are flot shown.
Generation ofrnottse EFNB2-fc
The coding sequence ofthe extracelluiar domains ofmouse EFNB2 from positions 29 to 684
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was cloned in-frame upstrearn of the human IgGl-Fc coding sequence in an expression
vector pCMVhFc. The constructs and pcDNA3 were then transfected into CHO/dhfr- celis
with Lipofectamine (Invitrogen, Burlington, Ontario, Canada). The ceils were cultured in
selection medium (aMEM without ribonucleosides and deoxyribonucleosides containing
5% dialyzed FCS, 0.01 mM methotrexate, 0.8 mg!ml G41$, and 0.1 mg/ml gentamicin).
After 2 wk of culture, well-isolated clones were handpicked and expanded in the selection
medium without G4 18. The cuLture supernatants were assayed by ELISA for human IgG
Fc-positive clones, which were then expanded. Fusion proteins were isolated from
supematants ofthe positive clone by protein A columns, then analyzed with 10% SDS-PAGE
to confirm their molecular sizes, and verified by N-terminal peptide sequencing (Sheldon
Biotechnology Center, McGill University, Montreal, Canada).
Lymphocyte preparation and culture
Ceils were flushed out from the BALB/c mouse spleen, and RBCs were lysed with 0.84%
NH4C1, as described eisewhere (28). The resuiting celis were referred to as spleen ceils.
Sptenic T celis were purified by deleting mouse IgG (H+L)-positive ceils from spleen ceils
with T ccli coiumns according to the rnanufacmrer’s instructions (Cedarianc, Homby,
Ontario, Canada). In some experiments, the T ceils were fractionated from spleen ceils into
CD4 and CD8 celis using magnetic beads (Miitenyi Biotec, Auburn, CA). The ceils were
cuitured in RPMI 1640 medium supplemented with 10% FCS, L-giutamine, and penicillin
streptomycin. Solid-phase EFNB2 and anti-CD3 were prepared by coating 96-well Costar
3595 plates (Costar, Cambridge, MA) overnight with anti-mouse CD3 (clone 2C11) in PBS
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at 4°C, followed by incubating EFNB2-Fc or normal human IgG (NHIgG; as a control;
Southem Biotechnology, Birmingham, AL) of different concentrations at 37°C for 2 h. The
plates were finally incubated on ice for 1—2 additional hours before use.
Flow cvtometiy
Flow cytomctry was used for measurernent of EFNB2R expression as well as EFNB2
expression in different ccli populations. BALB/c spleen cells were stained with EFNB2-
fc/goat anti-human IgG-PE or with goat anti-EfNB2 (R&D Systems, Minneapolis,
MN)/donkey anti-goat IgG-PE (Cedarlane). For the second color, anti-Thyl .2-FITC (Caltag
Laboratories, Burlingame, CA), anti-B220-FITC (clone RA3 -6B2), and anti-f4/80-fITC
(clone CI:A3-1) were used. To measure the expression of activation markers on T ceils,
spienic T celis were stained with anti-Thy 1 .2-PE in combination with anti-CD25-FITC
(clone M-A251), anti-CD44-fITC (clone 1M7), anti-CD54-FITC (clone HA58), or anti
CD69-FITC (clone FN50). All ofthese mAbs were from BD PharMingen (San Diego, CA),
unless indicated otherwise.
/H]-thymidine uptake assay
Spienic T cells were cultured in 96-well Costar plates coated with different mAb or
recombinant proteins, and [3Hjthymidine uptake was measured, as described previously (29).
Cytotoxic T-ceÏl assay
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The assay was performed as detailed earlier (30). Briefly, C57BL/6 or transgenic 2C mouse
spleen ceils (H2b with rnost of their T celis specific to Ld; 0.4 x 106 cells/well) were
stimulated with an equal amount of mitomycin C-treated BALB/c mouse spleen celis (H2d)
in flat-bottom 96-well plates, which were precoated with goat anti-human IgG (5 jig/ml)
followed by EFNB2-Fc or NHIgG coating (both at 10 tg/m1). The ceils were cultured in the
presence of 10 U/ml IL-2 for 6 days. On day 6, celis receiving the same treatrnent were
pooled and counted, and their CTL activity was measured by a standard 4-h 51Cr release assay,
using 51Cr-labeled P815 cells (H2d) as targets at different E:T ratios. The lysis percentage of
the test sample was calculated as follows:
% lysis (cpm of the test sample - cpm of spontaneous release)/(cpm of maximal release -
cpm of spontaneous release).
Cytokine measurem en t
Culture supematants of splenic T cells placed in anti-CD3- and/or EFNB2-Fc-coated wells
were harvested 1—3 days after initiation of culture. IL-2, IL-4, and IFN-y in the supematants
were quantified by ELISA (R&D Systems) according to the manufacturer’s instructions.
Laser scan n ing confocal microscopy
Five million BALB/c splenic T ceils were first blocked with 100 pi ofPBS containing 2%
BSA on ice for 30 min. Five micrograms of EFNB2-Fc and 1 jig of biotinylated anti-CD3
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(clone 2C 11; hamster mAb) were then added to the ceil suspension, which was incubated for
another 30 min on ice. Afier washing with coid PBS, the celis were reacted with goat anti-
hamster IgG (5 jig/sample) for 30 min on ice. The celis were washed with cold PBS and
transferred to 100 iI ofwarm PBS to start the cross-Ïinking process at 370 C. The ceils were
then immediately fixed with 2 ml of 3.7% formalin at room temperature for 10 min. For TCR
and EFNB2R staining, the celis were reacted with streptavidin-Alexa Fluor 594 (1 ig/samp1e)
and goat anti-human IgG-Alexa Fluor 48$ (1 jig/106 celis) on ice for 30 min. For raft and
EFN32R staining, the procedure was similar to that for TCR and EFNB2R staining, but
choiera toxin-Alexa Fluor 594 (0.5 jig/sample) was used in place of streptavidin-Alexa Fluor
594. The stained ceils were then washed with PBS and mounted on siides with Prolong
antifade mounting medium (Molecular Probes, Eugene, OR). The siides were examined
under a confocal microscope. Digital images were processed with Photoshop (Adobe, Seattle,
WA).
InununobÏotting
Twelve-well plates were coated ovemight with anti-CD3 (0.8 .tg/ml, 500 jil/well) at 4°C.
After washing, the wells were incubated with EFNB2-Fc or NHIgG (both at 10 ig/m1, 500
l1l/well) at 37°C for 1—2 h, and then at 0°C for another 2 h. BALB/c splenic T ceils were
seeded in the precoated plates at 5 x 106 cells/welt, and the plates were centrifuged at 22$ x g
for 5 min to achieve rapid contact between the cells and the bottom ofthe culture wells. The
cells were then cultured at 37°C for 2 h before being harvested. The remainder of the
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procedure has been detailed in our previous publication (28). Briefly, the harvested celis were
washed and iysed in lysis buffer for 10 mm; the cleared lysates were resolved in 10% SDS
PAGE with 50 tg of protein/iane and were then biotted onto polyvinylidene difluoride
membranes. The membranes were sequentiaiiy hybridizcd with rabbit anti-phospho-p38
MAPK Ab followed by rabbit anti-p38 MAPK Ab, or with rabbit anti-phospho-p44/42
MAPK Ab foiiowed by anti-p44/42 MAPK. Ail ofthe Abs used in immunoblotting was from
New Engiand Biolabs (Mississauga, Ontario, Canada). Signais were reveaied by ECL.
RESULTS
Expression oJEfNB2 in the thym us and spleen according to in sitit hybridization
The BALB/c mouse thymus and spleen were examined by in situ hybridization using DIG
iabeied EFNB2 antisense and sense probes. As shown in fig. 1, EfNB2 was prominently
cxpressed in the thymic cortex and spleen white pulp. This expression pattem suggests that
EFNB2 might have a function in lymphocytes cells, particularly T ceiis.
EFNB2 and EfNB2R expression in T cells, B celÏs and monocytes/macrophages according to
flow cytometîy
We first examined EfNB2 expression (fig. 2A). Spienic T cells were doubie-iabeled with
anti-CD3/anti-EFNB2 and anaiyzed by flow cytometry. Celis with EFNB2 intensity above
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the control goat 1gO were referred to as EFNB2-positive ceils. In freshly prepared ceils, 7.1%
T ceils were EFNB2 positive. The T ceils rapidly up-regulated their EFNB2, and EFNB2-
positive T celis reached 23.2% after ovemight culture in medium. The expression ofEFNB2
on CD4 and CD$ celis was similar (f ig. 2C); after ovemight culture, 26.1 and 28.8% ofCD4
and CD8 celis, respectively, became EFNB2 positive. Activation of CD3 T celis by anti
CD3 or anti-CD3 plus anti-CD2$ (both on solid phase) for 24—4$ h did not augment EfNB2
expression, as shown in Fig. 2D; actually, there was a moderated decrease ofEfNB2 ceils at
24 h after the activation. EfNB2 was minimally expressed in freshly isolated or cultured B
ceils (3220f) (0.2 and 4.9%, respectively) (Fig. 2A). Monocytes/macrophages (F4/20) were
another ceil population showing significant expression of EFNB2 afier culture, with 5.2%
positive in freshly isolated ones and 31.2% positive after culture (Fig. 2A).
Next, we examined EFNB2R expression on these ceils (Fig. 23). EFNB2Rs were
predominantly expressed on T ceils, with 8.6% positivity in freshly isolated T ceils and
42.9% positivity in cultured ones. Both CD4 and CD8 cells expressed EfNB2R, but more
CD4 ceils expressed EFNB2R than CD8 celis afier ovemight culture (47.9 vs 28.9%) (Fig.
2C). The expression of EFNB2R was not significantly affectcd by the status of T ceil
activation; T celis activated by solid-phase anti-CD3 or anti-CD3 plus anti-CD2$ for 24 or 48
h had no increase in EfNB2R expression, but a moderate decrease ofthe expression could be
consistently observed at 24 h (Fig. 2D). B cells had minimal receptor expression either before
(data not shown) or after culture (Fig. 23). Sorne monocytes/macrophages (16.9%) become
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EFNB2R positive after culture (Fig. 2B).
The low expression of EfNB2 and EFNB2R in fteshly isolated T ceils and their subsequent
up-regulation after culture was intriguing. We suspected that some semm factors were
responsible for this phenomenon. To test this possibility, we cultured the T celis ovemight in
100% fresh untreated mouse serum as well as in 100% heat-inactivated mouse serum. As
shown in Fig. 2E, T cells (CD3j cultured in the former but flot the latter failed to up-regulate
both EFNB2 and EFNB2R. It is probable that heat-sensitive serum proteases rapidly cleave
EFNB2 and EfNB2R from the celi surface. Such cleavage is not unusual for many celi
surface molecules, including several TNf family members. Altematively, a heat-sensitive
factor(s) in serum might be suppressive ofEFNB2 and EFNB2R expression.
These resuits revealed the expression pattem ofboth EFNB2 and EFNB2R in T ceils, B celis,
and monocytes/macrophages, and suggest that EFNB2 might have an important effect on T
celis in the form of either T cell-T ccli collaboration or T ceil-monocyte/macrophage
interaction during Ag presentation.
EfNB2 enhances T-celÏprohferation and modulates activation marker expression
The predominant expression of EFNB2R on T cells led us to investigate whether EFNB2
could modulate T ceil function. For this purpose, both anti-CD3 mAb and EFNB2-Fc were
put on solid phase. Anti-CD3 (at a suboptimai concentration) or EFNB2-fc (at an optimal
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concentration) alone caused negiigible T ceil proliferation (f igs. 3, B and C), but EFNB2-fc
dose-dependently induced their proliferation in the presence of anti-CD3 (A). Next, T celis
were cultured in welis coated with an optimal amount ofEFNB2-Fc and various amounts of
anti-CD3. As shown in fig. 3B, EFNB2-Fc but not NHIgG (a negative control for EfNB2-
Fc) augmented T celi proliferation when anti-CD3 was used at different concentrations. This
resuit suggests that EfNB2R cross-linking reduces the T ccli response threshold, and that
EfNB2-expressing celis might be able to costimulate T celis. We also compared the
costimulation by EFNB2-fc with that by anti-CD28 mAb (fig. 3C). The magnitude of
costirnulation mediated by EfNB2R was lower than the classical costimulating moiccule
CD28. CD4 celis and CD$ ceils were both sensitive to EFNB2 costimulation, because their
proliferation was simifarly augmented by solid-phase EFNB2-Fc in the presence of
suboptimal anti-CD3 (Fig. 3D).
The T ccli response to EFNB2 was also assessed by their expression of activation markers. T
cells were stimulated with solid-phase anti-CD3 alone (at a suboptimal concentration) or
solid-phase anti-CD3 plus EfNB2-fc (at an optimal concentration). As shown in Fig. 4,
anti-CD3 alone (shaded area) at such a concentration was flot abie to up-regulate the
activation markers cxamined, i.e., CD25, CD44, CD54, and CD69. After combined
stimulation with anti-CD3 and EFNB2-Fc, CD69 but flot CD25, CD44, or CD54 was
significantiy up-regulated. In contrast, the classical costimulation by anti-CD2$ drastically
enhanced ail of the activation markers examined, and CD69-positive T ceils reached 61.5%,
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which was 2-fold higher than that of EFNB2-fc-costimulated celis. The resuits indicate that
EfNB2R can costimulate T celis, but this is quantitatively and quatitatively different from
CD28.
EfNB2 enhances T-ceÏl effectorfitnctions
We next examined the effect of EfNB2 on T celi effector functions, such as lymphokine
production and CTL activity.
Again, T ceils were stimulated with solid-phase anti-CD3 alone (at a suboptimal
concentration) or in combination with EFNB2-Fc or anti-CD2$ (both at optimal
concentrations and on solid phase). NHIgG was used as a negative control for EFNB2-Fc.
Anti-CD3 alone did not trigger lymphokine production. Anti-CD28 costimulation drastically
induced IL-2, IL-4, and IFN-y, as expected (Fig. 5). However, EFNB2-Fc costimufation
augmented only IFN-y but flot IL-2 or IL-4 release. The IFN-y level stimulated by EFNB2-
Fc was lower than, but of the same order of magnitude of that induced by anti-CD28
costimulation. The lack of IL-2 and IL-4 production was not due to a shift of secretion
kinetics during EFNB2 costimulation, because no production of these lymphokines was
obsewed during any tirne between days 1 and 3 afier culture. This again demonstrated the
qualitative difference between costimulation mediated by CD28 and EFNB2R.
In EfNB2-Fc-coated wells, H2d (BALB/c)-stimulated CIL development ofthe C57BL/6 T
ceils (Fig. 6A) or Ldspecific 2C T ceils (B) was greatly enhanced, whereas control NHIgG
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had no such effect. As 2C T ceils are predominantly CD8 cells (>85% Thy1.2 cells were
CD$ ceils, and <3% Thyl.2 celis were CD4 ceils), our resuit suggests that EfNB2 can
directly costimulate CD$ celis to achieve CTL differentiation with littie dependence on CD4
help. This resuit is consistent with the fact that CD8 ceils in the absence of CD4 ceils could
be directly costimulated to proliferate by solid-phase EfNB2-Fc (f ig. 3D). The
costimulatory effect could be observed only when EFNB2-Fc was on the solid phase in the
beginning of the culture. Soluble EFNB2-fc added to the culture on the last day before the
CTL assay or during the CTL assay had no effect (data not shown). This is in agreement with
the notion that EFNB2 provides costimulation, which is an eariy event during T ccli
activation and differentiation.
The results of this section demonstrate that EfNB2 can selectively enhance certain T celi
effector functions, likely by promoting costirnulation to T cells during their early stage of
activation.
EfNB2 triggers signaling events in T celis
To understand the molecular basis of EfNB2 costimulation, wc examined transiocation of
EfNB2Rs and TCR, and thcir relationship with lipid rafts on T cdl membranes immediately
after TCR cross-linking. T cells were preincubated with anti-CD3-biotin, followed by a
second Ah on ice. CD3 cross-iinking started when the celis were transferred to 3 7°C. The
TCR complex was stained by streptavidin-Alexa fluor 594 in red; EFNB2Rs were stained by
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EFNB2-Fc followed by anti-human IgG-Alexa Fluor 488 in green; and the lipid rafis in the T
ceil membrane were stained by choiera toxin-Alexa Fluor 594 in red. In resting T ceils, rafts,
TCR, and EFNB2Rs were distributed throughout the cell surface as small speckies. After
1 0-min cross-linking with anti-CD3, TCR rapidly polarized and formed a cap in one end of
the celi. EfNB2Rs also congregated, and they colocalized with TCR (fig. 7A). Such
cocapping lasted >20 min (data flot shown). Afier CD3 cross-linking, rafts underwent
congregation and formed caps, but this process was siower than TCR capping and was
completed at 20 min (Fig. 73). EFNB2R congregation preceded rafi congregation, but
eventually at 20 mm, EFNB2Rs translocated into the raft caps, suggesting that EFNB2Rs,
probably like the TCR complex, only transiently associated with the rafis during TCR
activation. Taken together, these data indicate that 1CR and EfNB2Rs flrst cocap, and then
both congregate to a raft cap on the ccii surface after TCR-cross-linking. This provides a
morphological base for EFNB2 to enhancc TCR signaling, because now both TCR and
EFNB2Rs are closely associated and located in aggregated rafis, which are scaffolds
accommodating many signaling molecules.
Next, in EFNB2-costimulated T celis, we examined MAPK activity, which is modulated in
other cell types when sorne Eph kinases are activated (3 1, 32, 33, 34). As shown in fig. sA, a
combination of solid-phase EFNB2-Fc and suboptimal anti-CD3 stimulation for 2 h led to
increased p38 MAPK and p44142 MAPK phosphorylation, a sign of their activation, whereas
anti-CD3 at suboptimal concentration had littie effect, according to immunobiotting. The
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membranes were reprobed with anti-p38 MAPK Ab or anti-p44/42 MAKP Ab, respectively,
and the total protein levcls ofthese kinases in ail ofthe lanes oftheir respective membranes
were similar. Therefore, these MAPK were activated afier EFNB2R-cross-!inking, and such
activation might be part ofthe EFNB2 costimulation program. To assess the relevance ofthe
EFNB2-up-regu!ated MAPK activity in T cel! activation, p38 MAPK- and p44/42 MAPK
specific inhibitors, SB2035$O and PD98059, respectively, were used. As shown in Fig. 8B,
both inhibitors, but not their nonfunctional structural analog SB272474, inhibited EFNB2-
enhanced T ce!! proliferation. This indicates that up-regulation of the MAPK activity is an
essential part of EFNB2 costimulation signaling.
DISCUSSION
In this study, the novel functions ofEFNB2 on T ce!! activities were revea!ed. In the immune
system, EfNB2 was expressed on T ceils and monocytes/macrophages, and its receptors
were mainly expressed on T ce!!s. Solid-phase EfNB2 could costimulate T ceils in the
presence of suboptima! TCR !igation. Such costimulation led to enhanced T cell pro!iferation
and IFN- production. These functional studies were consistent with our previous report (17)
in the human system using mAb against EphB6, which is one ofthe receptors EFNB2 binds.
However, the current findings went significant!y beyond the said report in severa! ways: 1) a
physiologica! relevant molecu!e, i.e., mouse EFNB2, was used in this mouse system, and
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thus, the resuits reflected flot only the effect ofEfNB2 through EphB6, but its overali effect
through ail the EphBRs it triggered, as would occur in vivo; 2) EFNB2 up-regulated CTL
activity, which was a new finding and a Iogical one; 3) ligation of TCR resulted in rapid
congregation of EFNB2Rs to rafis, to which TCR complex also translocated; and 4) EFNB2
costirnulation augmented activation ofnot only p38 MAPK, as with anti-EpbB6-stimulated
human T ceils, but also p44142 MAPK.
As a general rule, an EFNB subfamily ligand associates with more than one specific EphB
receptor. For EFNB2, it can bind to EphBÏ, -2, -3, -4 (35), and -6 (36). Arnong these, EphB2
(14), EphB4 (15) and EphB6 (16) are relevant to our study, because they are expressed in the
T celi compartment. According to in situ hybridization (data not shown), both EphB4 and
EphB6 were expressed in the same region of the lymphoid organs, i.e., thymic cortex and
spleen white pulp, like EFNB2. Such colocalization creates a possibility for interactions
between EphB4 and EFNB2 ceils, and between EphB6 and EFNB2 ceils. We are
culTently examining whether other EphBs are also expressed in these regions. It is quite
possible that other EphBs, in addition to EphB6, are involved in mediating EFNB2-triggered
T celi costimulation: soluble EphB4 moderately inhibited solid-phase EfNB2 costimulation
on wild-type T ceils, but such inhibition was more significant in EphB6 gene knockout T
celis (data not shown), aithough the inhibition was stiil flot complete. This suggests the
involvement of both EphB4 and EphB6 in EFNB2-triggercd costimulation, and thc
remainder ofthe uninhibited costimulation could be mediated by othcr EphBs.
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUANG YU 61
We noticed that, in this study, EfNB2 costimulation failed to enhance CD25 and CD54
expression on T celis, whereas in our previous study, anti-EphB6 mAb was able to do so (17).
If EphB6 is one of the receptors EfNB2 acted on, EFNB2 stimulation, in theory, should
achieve effects no less than that achicved by anti-EphB6 rnAb. How do we explain the
discrepancy? First, our previous study was conducted in the human system, whereas the
current one was performed in the murine system. The species difference is aiways a possible
explanation. More likely, this might be caused by a different affinity between the mAb and
the natural ligand EFNB2.
A recent ciystal structure study has suggested that, before binding to its receptors, EFNB2
might forrn homodimers on the cell surface (37). Upon binding with EphB2 on another cdl,
two EFNB2 molecules and two EphB2 molecules on two different ceils might form very
stable tetramer complexes. It is conceivable that EFNB2 might similarly interact with other
EphBs. This might be the molecular basis for EFNB2 to provide strong and lasting
costimulation to T ceils. Lymphoid organs are densely packed with EfNB2T ceils as weIl as
other EFNB2 ceils. EfNB2 on these ceils might constantly stimulate EfNB2R on the
neighboring T ceils, and reduce their response threshold to foreign Ags. This is reminiscent
ofrecent findings that, in vivo, T ceils constantly receive low tevel stimulation from self-Ag
on neighboring ceils, and such stimulation promotes T celi sensitivity to the foreign Ags (38,
39). To maintain active signaling pathway downstream of EfNB2R due to the possible
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constant interaction with its Iigands, continuous expression of new EfNB2Rs with
simultaneous shedding of the old ones might be a valid strategy. We found that T celis
cultured in untreated serum had low EFNB2R and EfNB2 expression, but the expression
drastically augmented when the serum was heat inactivated. This suggests that rapid
shedding ofthese surface molecules is indeed a possibitity, atthough this needs confirmation.
With that said, we cannot exciude that this is due to serum inhibitory factors. Further
investigation in this regard is warranted.
EFNB2 costimulation seems qualitatively different from anti-CD2$ costimulation in that
only IfN-y but flot IL-2 or IL-4 was produced in the former. n fact, similar findings were
observed using anti-EphB6 mAb (17), or EFNB2 (the current study), or EFNBY and EFNB3
(data flot shown). Thus, this seems to be an intrinsic property of costimulation mediated by
EphBs. Consistent with this finding, we found that solid-phase EfNB2 augmented CTL
activity, for which increased IFN- y is likely a contributing factor. Naturally, the enhanced
CTL might benefit from other cellular activities that EFNB2 promoted, such as T ceil
proliferation, which could amplify the number ofthe CTL precursors.
The critical role of lipid rafts in TCR signaling has been increasingly appreciated. Some TCR
signaling molecules, such as Src kinase, linker for activation of T celis, and Ras are
constitutively situated in the rafts (40, 41, 42), whercas others, such as CD3Ç-associated
protein-70, Vav, phospholipase C-y!, protein kinase C-0, and Ii<B kinase components
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transiocate into rafts afier TCR triggering (43, 44, 45, 46). Such transiocation enables TCR to
use these moiecules in the scaffold of rafts to accomplish its signaling. We studied the
relationship between EFNB2R and rafis under various conditions. Cross-linking EFNB2Rs
using EFNB2 in the absence or presence of suboptimal TCR cross-linking did flot alter the
EfNB2Rs or raft distribution, and they remained eventy scattered on T celi surface (data not
shown). Only rather strong TCR cross-linking (as shown in Fig. 7) resulted in caps
containing EfNB2Rs, rafts, and TCR. EFNBR2 capping had different kinetics from raft
capping, suggesting that EFNB2Rs are flot constitutively located in rafts. This indicates that
EfNB2R belongs to the second categoiy of signaling molecuies (likely CD3Ç et al., as
discussed above) that move to the rafis to assist TCR signaling oniy afier TCR have already
been triggered.
For proper T ceil activation, Ras and Rac signaling pathways need to be mobilized. Ras
activation leads to activation ofp44/42 MAPK kinases, which, in tum, resuits in the synthesis
and activation of various transcription factors. In contrast, activation ofRac and Cdc42 small
G proteins leads to p38 MAPK activation, which is essentiat for cytoskeleton reorganization.
Such reorganization is now known to 5e pivotai for the T ceil signaling (47). We have found
that the activities of both p44/42 and p38 MAPK are enhanced in the presence of EfNB2
costimulation, and this is consistent with the roles of these MAPKs in T ccli activation.
Recently, it has been reported that EphB2 activation resuits in inhibition of p44/42 MAPK in
neuronal ceils (34), and that EphA activation leads to inhibition of this kinase in several cell
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unes of endothelial and epithelial origin (48). Obviously, these reports deal with ce!! types
different from those in our study. The consequence is different as well. In neuronal ce!!s,
endothelia! ce!ls, and epithe!ia! ce!!s, Eph activation does flot induce celi proliferation, whi!e
in T ce!!s, it does. Further comparative studies on the EFNB2R signa!ing in T celis and
nonimmune cel!s wil! be interesting.
We have demonstrated the costimu!atory effects of EFNB2 on mouse T celis in this study.
The function of Ephs and their !igands in immune regulation represents a new domain of
research in immunobiology and deserves more attention.
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figure]. EfNB2 expression in the thymus and spleen according to in situ hybridization
Thymus and spleen sections were hybridized with DIG-labeled anti-sense or sense EFNB2
probes. The liver was used as a negative control. The original magnification was 100 X.
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figure 2. Flow cytometly analysis ofEfNB2 and EFN32R expression on immune celis
Ail experiments were performed more than twice, and were reproducible. Representative
resuits are shown. Two-color flow cytometry was used to assess EFNB2 or EfNB2R
expression on T celis, B celis and monocytes/macrophages; T celis were stained with
anti-CD3; B celis, with anti-B220; and monocytes/macrophages, with f4180. One-color flow
cytometry was used to assess EFNB2 or EFNB2R expression on magnetic beads-purified
CD4 or CD8 ceils. A: EFNB2 expression on CD3 T celis, B220 B celis or F4/80
monocytes/macrophages. B: EFNB2R expression on CD3 T celis, B220 B celis or F4/8OE’
monocytes/macrophages. C: EFNB2 and EFNB2R expression on magnetic beads-purified
CD4 or CD8 celis. D: Kinetics ofEFBB2 and EFNB2R expression on CD3 T ceils activated
with solid phase anti-CD3 (suboptimal) or anti-CD3 (suboptimal) plus anti-CD2$. E: EfNB2
and EFNB2R expression on CD3 T celis cultured in 100% untreated or heat-inactivated
mouse serum. The percentages of positive celis are indicated.
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Figure 3. EfNB2R crosslinking enhances the T-cell response to 1CR stimulation
Ail experiments were conducted more than 3 times and were reproducible. Representative
resuits are shown. The affix “anti” used in conjunction with mAbs is simplified as “Œ” in this
and ail the other figures ofthis article. Ail the concentrations indicated in the figure legends
represent those employed during the coating procedure. Normal human IgG (N}IIgG) served
as a control for EFNB2-Fc. In some cases, the wells were oniy coated with anti-CD3,
followed by PBS incubation (PBS), and were used as additional blank controls. BALB/c T
celis were cultured in weils coated with (A) a suboptimal amount of anti-CD3 (0.8 ig/m1)
and different amounts of EfNB2-Fc; (B) a fixed optimal amount of EFNB2-Fc (10 tg/ml)
and different amounts of anti-CD3; or (C) a suboptimal amount of anti-CD3 (0.8 tg/m1)
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along with optimal arnounts of anti-CD2$ or EFNB2-Fc (both at 10 tg/ml). Magnetic
beads-purified CD4 or CD$ ceils were also cultured in wells coated with EFNB2-Fc,
NHIgG, or anti-CD2$ in the presence of suboptimal solid phase anti-CD3 (D). The celis
were cultured for 48 h, and their 3H-thymidine uptake in the last 16 h was measured. Means ±
$D of the cpm from triplicate samples are shown.
fig. 4
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figure 4. Activation rnarker expression ofEfNB2-fc-costirnulated T cetis
Ail experiments were carried out more than 3 times and were reproducible. Representative
resuits are shown. BALB/c T celis were cultured in wells coated with anti-CD3 mAb (0.8
ig/ml) plus EFNB2-Fc or anti-CD28 (both at 10 j.ig/ml). Their activation marker expression
at 24 h was assessed by 2-color ftow cytometry, using anti-Thyl .2-PE for T-cell gating, and
anti-CD25 -FITC, anti-CD44-FITC, anti-CD54-fTTC, and anti-CD69-fITC for activation
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markers. Percentages represent activation marker positive ceils among Thyl.2 positive cells
(solid unes) after deducting fluorescence in celis stimulated with suboptimal anti-CD3 alone
(shaded areas).
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figure 5. SoÏidphase EfNB2-fc strongly augments IfN-y but not IL-2 or IL-4 production by
anti- CD3-stinzuÏated T ceÏÏs
Mouse spleen T celis were stimulated with solid phase EfNB2-Fc (10 ig!ml) in the presence
ofa suboptimal concentration of anti-CD3 (0.8 jig/ml). Anti-CD28 (10 mg/ml) and NHIgG
were used as positive and negative controls, respectively. The culture supernatants were
harvested from days 1 to 3, and cytokines in the supernatants were measured by ELISA. The
experiment was performed more than twice and was reproducible. Means ± SD of
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representative resuits are shown.
Fie. 6
Figure 6. Effect ofsolid phase EFNB2-fc on CTL developrnent
C57BL/6 mouse (A) or 2C mouse (B) spleen ceils were mixed with an equal amount of
mitomycin C-treated BALB/c mouse spleen cells and seeded in flat-bottorned 24-well plates,
which were pre-coated with EFNB2-fC or NHIgG (both at 10 ig/ml), or flot coated
(Medium). Afler 6 days, CIL activity in the stimulated ceils was rneasured by a standard 4-h
51Cr-release assay, using P815 cells as targets. The samples were tested in triplicate, and
means ± SD ofthe percentage oftarget ceil lysis are shown. The experiments were performed
twice with similar resuits, and the data of a representative experiment are presented.
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Figure 7. Rapid colocaÏization ofEFNB2 receptors with TCR and rafi caps after anti-CD3
crosslinking
BALB/c spleen T celis were crosslinked with anti-CD3 for 0, 10 or 20 mm, as indicated. The
locations ofTCR (stained with biotin-anti-CD3 foilowed by Alexa Fluor 594-streptavidin in
red) (A), EfNB2 receptors (stained with EFNB2-Fc followed by Alexa 488-anti-human IgG
in green) (A and B), and rafis (stained with Alexa Fluor 594—cholera toxin (CT) in red) (B)
were revealed by confocal microscopy. Ail experiments were conducted more than 3 times
and were reproducible. Representative results are shown.
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figure 8. Activation ofp38 MAPK andp44/42 MAPK in Tcells by soÏid phase EFNB2-fc
A. Immunoblotting ofp38 andp44/42 MAPK
T celis were added to welïs coated with EFNB2-Fc or NHIgG (both at 10 tg/ml) in the
presence ofa suboptimal amount ofanti-CD3 (0.8 ig/ml). The ceils were harvested after 2 h,
and analyzed by immunoblotting. Arrows indicate signais of p38 phospho-MAPK and total
p38 MAPK of the same membrane, and signais of p44142 phospho-MAPK and total p44142
MAPK ofthe same membrane.
B. p38- andp44/42-specfic inhibitors inhibit EfNB2-costirnulated T-cellprolferation
T celis were pre-incubated for 1 h in complete culture medium containing the p38
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MAPK-specific inhibitor SB203580, p44/42-specffic inhibitor PD98059, its non-functional
structural analog SB272474 (ail at 10 .iM), or vehicle DMSO (dirnethyl sulfoxide, 0.1%).
The ceils were then transferred to wells coated with EFNB2-Fc (10 ig/m1), anti-CD3 mAb
(0.8 pg/ml), or both, and cultured for 48 h. 3H-thymidine was added to the culture for the last
8 h, and thymidine uptake by the ceils was measured.
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ABSTRACT
Ephrins (EFN) are ceil-surface ligands of Ephs, the largest family of celi-surface receptor
tyrosine kinases. The function of EFNs in the immune system has flot been well studied,
although some EFNs and Ephs are expressed at high levels on certain icukocytes. We report
here that EFNB3 and its receptors (collectively called EFNB3Rs, as EfNB3 binds to
multiple EphBs) were expressed in peripheral T cells and monocytes/macrophages, with T
cells being the dominant EFNB3 and EfNB3R cell type. Solid-phase EFNB3-Fc in the
presence of suboptimal anti-CD3 crosslinking enhanced T-cell responses in terms of
proliferation, activation marker expression, interferon-y but flot interlcukin-2 production, and
cytotoxic T-cell activity. EFNB3R costimulation in the presence of phorbol 12-myristate 13-
acetate was insensitive to cyclosporin A, similar to CD28 costimulation, suggesting they
might share a part ofthe signaling pathway. Afler crosslinking, T-cell receptor and EFNB3R
congregated into aggregated rafts, and this provided a morphological basis for signaling
pathways of T-cell receptor and EFNB3R to interact. Solidphase EfNB3-fc augmented p38
and p44/42 MAPK activation further downstream of the signaling pathway. These data
suggest that EFNB3 is important in T-cell/T-cell and T-cell/antigen-presenting ccli
collaboration to enhance T-cell activation and function.
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INTRODUCTION
Full T-ceil activation requires costimulation in addition to T-cell receptor (TCR) ligation.
Costimulation can be conferred by ceil-surface molecules. For example, the well studied
B7. 1 and B7.2 are two prototype costimulatory moiecules expressed on antigen-presenting
ceils (1). Additional members of the B7 family with costimulatory function have been
documented recentiy (2). Certain ceil-surface adhesion molecuies (3) and some membrane
bound turnor necrosis factor famiiy members (4, 5) are capable of costimutation as weli. In
generai, the costimulation increases the affinity and prolongs the interaction between T ceils
and antigen-prescnting celis; it also allows the integration of costimulation-triggered
signaling pathways with that of TCR. As a result, the T-cell response threshold to Ag is
reduced, and the response to Ag is enhanced.
Ephrins (EFN) are celi-surface ligands ofEpli receptor tyrosine kinases. EFNs are classified
into A and B subfamilies; the former consists of six glycosyiphosphatidylinositoi-anchored
membrane proteins (EfNA1—6), and the latter consists of three transmembrane proteins
(EFNB1—3) (6). EFNBs are capable of reverse transmission of signais into cetis, atthough
they are iigands (7). EFNAs bind to EphAs with ioose specificity, and, likewise, EFNBs bind
to EphBs (8), with the exception of EphA4, which binds both EFNAs and EFNBs (9).
Because both EFNs and Ephs are celi-surface proteins, they interact with each other in
proximity and control cdl patteming as well as directional growth. Such functions are weli
demonstrated in the central nervous system (10), during angiogenesis (li), and as reported
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recently (12, 13), in intestinal development and remodeling.
Some members ofthe Eph and EFN families are expressed in lymphoid organs and on some
leukocytes (14—29), but we are really in the veiy beginning of our understanding of the
function of this largest family of receptor tyrosine kinases and their ligands in immune
regulation. We have reported previously that EphB6 crosslinking by mAb leads to signal
transduction and apoptosis ofJurkat T cells (26) as well as to augmentation of normal human
T-celJ responses (20). Preliminary examination of EphB6 mice shows no gross anomaly in
the thymic structure and thymocyte populations (21), suggesting compensatory mechanisms
at work. In this study, we investigated the expression ofEFNB3 and its receptors in immune
ceils and explored its function in regulating T-cell activity.
EXPERIMENTAL PROCEDURES
In situ Hybridization
A 522-bp cDNA fragment of mouse EFNB3 cDNA from positions 160 to 681 (accession
number Af02528$ [GenBankl ) was fetched with PCR from a mouse embryonic tissue
cDNA library and cloned into pGEM-4Z (Invitrogen). The resulting constmct, pGEM-4Z-
m33, served to transcribe antisense probes with SP6 RNA polymerase or to transcribe sense
probes with T7 RNA polymerase using digoxigenin RNA labeling kits (Roche Diagnostics,
Lavai, Quebec, Canada). In situ hybridization was canied out according to instructions from
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the kit manufacturer.
Generation ofliouse EFNB3-Fc
The coding sequence ofthe extracellular domains of mouse EFNB3 from positions 34 to 717
was cloned in-frame upstream of the human IgGl-fc coding sequence in expression vector
pCMVhfc. The constrncts and pcDNA3 were then transfected into Chinese hamster
ovary/dhfr- cclls with LipofectAMiNE. The celis were cultured in selection medium (Œ
minimum Eagle’s medium without ribonucleosides and deoxyribonucleosides containing 5%
dialyzed fetal caif serum, 0.01 mM methotrexate, 0.8 mg/ml G41$, and 0.1 mg/ml
gentamycin). Stably transfected clones were handpicked after 2 wceks of culture. fusion
proteins were isolated from supematants by protein A columns and verified by N-terminal
peptide sequencing (Sheldon Biotechnology Center, McGill University, Montreal, Quebec,
Canada).
Lymphocyte Freparation and Citititre
Ceils were flushed out from the BALB/c mouse spleen, and red blood celis were lysed with
0.84% NH4CI, as described elsewhere (30). The resulting celis were referred to as spleen
ceils. Spleen T cells were purified by deleting mouse IgG (H+L)-positive cells from spleen
cells with T-cell columns according to the manufacturers instructions (Cedarlane, Hornby,
Ontario, Canada). In some experiments, CD4 and CD8 cells were positive-selected from the
spleen cells by magnetic beads (Miltenyi Biotec, Auburn, CA). The ceils were cultured in
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RPMI 1640 medium supplemented with 10% fetal caif serum, L-glutamine, and penicillin
streptomycin. Solid-phase EFNB3 and anti-CD3 were prepared by coating 96-well Costar
3595 plates ovemight with anti-mouse CD3 (clone 2C1 1) in phosphate-buffered saline (PBS)
at 4 °C, followed by incubating EFNB3-Fc or, as a control, normal human IgG (NHIgG)
(Southem Biotechnology, Birmingham, AL) of different concentrations at 37 oc for 2 h,
followed by an additional 2-h incubation on ice. In some experiments, CD4 and CD8 cells
were positive-selected from the spleen cells by magnetic beads (Miltenyi Biotech). For
mixed lymphocyte reaction (MLR), spleen ceils from BALB/c mice were treated with
mitomycin C and mixed with C5 7BL/6 spleen cells at a 1: 1 ratio (8 x 1 O ceils at 200 tl/well).
The cells were cultured in the presence of NHIgG or Ephs (Eph A4, EphB3, and EphB4;
R&D Research, Minneapolis, MN) for 5 days before being harvested.
3H-thymidine Uptake Assay
Lymphocytes were cultured in 96-well costar 3595 plates coated with different mAbs,
recombinant proteins, or reagents in solution. The cells were pulsed with [3H]thymidine for
the last 16 h of culture, and [3H]thymidine uptake was measured, as described previously
(31).
ftow Cytomet.’y
Flow cytometry was employed for the measurement of EFNB3 expression as weII as
EfNB3R expression in T-cell populations. BALB/c spleen cells were stained with goat
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anti-EfNB3 (R&D Systems) followed by donkey anti-goat IgG-PE (Cedarlane) or with
biotinylated EFNB3-Fc followed by streptavidin-PE. Anti-ThyÏ.2-fITC (Caltag
Laboratories, Burlingame, CA) was used for the second color. To measure the expression of
activation markers on T cells, spleen T cells were stained with anti-Thyl.2-PE in
combination with anti-CD25-FITC (clone M-A25 1), anti-CD44-FITC (clone 1M7), anti
CD54-fITC (clone HA58), or anti-CD69-fITC (clone fN50). Ah of these mAbs were
obtained from PharMingen, unless indicated otherwise.
Cytotoxic T Lymphocyte (CTL) Assay
The assay was performed as detailed earhier (32) using transgenic 2C mouse spleen cells (in
H2b background with most oftheir T ceils specific to Ld, 0.4 x 106 cells/well) as responders,
mitomycin C-treated BALB/c mouse spleen cells (H2d) as stimulators, and 51Cr-labeled
P815 cells (H2d) as targets. This system is very sensitive and has a high signal-to-noise ratio
because ofthe high frequency of Ld-specific precursor T cells (30).
The lysis percentage ofthe test sample was calculated as follows:
% lysis (cpm of the test sample
- cpm of spontaneous release)/(cpm of maximal release -
cpm of spontaneous release).
Cytokine Measurem en t
Culture supematants of T cells placed in anti-CD3-coated and/or EFNB3-fc-coated wells
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were harvested 1—3 days after the initiation of culture. IL-2, IL-4, and IFN-y in the
supematants were quantitated by enzyme-linked immunosorbent assay (R&D Systems)
according to the manufacture?s instructions.
Coîfocal Microscopy
Five million BALB/c T celis were reacted on ice for 30 min with 5 tg ofEFNB3-Fc and 1 jig
of biotinylated anti-CD3 (clone 2C 11, hamster mAb). After washing, the ceils were
incubated with goat anti-hamster IgG (5 g/samplc) for 30 min on ice. They were then
washed with cold PBS and transfened to warm PBS to start the crosslinking process at 37 oc
for different time periods; this was followed by immediate fixation with 3.7% formalin. For
TCR and EfNB3R staining, the ceils were rcacted with streptavidin-Alexa Fluor 594 (1
tg/samplc) and goat anti-human IgG-Alexa Fluor 48$ (Ï tg/106 celis) on ice for 30 min. For
raft and EFNB3R staining, the procedure was similar to that described above, but choiera
toxin-Alexa Fluor 594 (0.5 tg/sarnpie) was used in place of streptavidin-Alexa Fluor 594.
The siides were examined under a confocal microscope.
fmnzunoblotting
Five million BALB/c T cells were reacted on ice for 30 min with 5 tg ofEFNB3-Fc and 1 jig
of biotinylated anti-CD3 (clone 2C 11, hamster mAb). After washing, the cells were
incubated with goat anti-hamster IgG (5 Ig/sample) for 30 min on ice. They were then
washed with cold PBS and transfened to warm PBS to start the crosslinking process at 37 °c
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for different time periods; this was followed by immediate fixation with 3.7% formalin. For
TCR and EFNB3R staining, the celis were reacted with streptavidin-Alexa Fluor 594 (1
ig/sample) and goat anti-human IgG-Alexa Fluor 488(1 tg/106 ceils) on ice for 30 min. For
raft and EFNB3R staining, the procedure was similar to that described above, but choiera
toxin-Alexa Fluor 594 (0.5 jsg/sarnple) was used in place of streptavidin-Alexa Fluor 594.
The siides were examined under a confocal microscope.
RESULTS
EFNB3 and EFNB3R Expression in Leukocvtes
EFNB3 expression at the mRNA level in the spleen was examined by in situ hybridization
with the liver serving as a negative control (Fig. 1). In the spleen, the EFNB3 signal was
detected in the white pulp, suggesting that lymphocytes express EFNB3.
The expression of EFNB3 and EFNB3Rs on resting and activated Thy1 T ceils was
investigated with flow cytometry by anti-EFNB3/anti-Thyl or EFN33-Fc/anti-Thy-1 two
color staining (Fig. 2A). EFNB3 was detectable in 18.8% resting T cells (cultured in
medium), and 24-h activation of T celis with solid-phase anti-CD3 did flot significantly
change the level ofEFNB3 expression (24.0%). EFNB3R was expressed on 30.4% resting T
celis; no apparent modulation of expression (30.1%) 24 h afier T-ecu activation was
observed. The expression ofEFNB3 and EFNB3R in resting CD4 and CD8 ceils (cultured in
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medium for 24 h) was determined by anti-EFNB3 or EFNB3-Fc one-color staining of
magnetic bead-purified CD4 and CD8 celis (f ig. 2C). The expression ofEFNB3 on CD4 and
CD$ ceils was similar (26.1 and 22.1%, respectively), although CD4 ceils expressed more
EfNB3Rs than CD$ cells (45.4 and 2 1.3%, respectively).
EFNB3 and EFNB3R were barely detectable in B celis (5.7 and 3.2%, respectively) but were
expressed in a significant percentage of monocytes/macrophages (20.4 and 35.5%,
respectively) (fig. 2B).
EfNB3 Enhances T-ceÏt ProÏferation ami Modulates Activation Marker Expression
Because EFNB3Rs are expressed in a significant portion of T celis, it is likely that EFNB3
plays a role in modulating T-cell function. Solid-phase EfNB3, in the presence of solid
phase anti-CD3, was used to assess this possibility. EfNB3-fc, but not a control protein
(normal human IgG), dose-dependently induced T-cell proliferation in the presence of a
suboptimal concentration of anti-CD3 (fig. 3A). When T ceils were stimulated with an
optima) amount of EFNB3-Fc and various amounts of anti-CD3, they proliferated dose
dependently in response to the latter (f ig. 33). We also compared the costirnulation by
EFNB3-Fc with that by anti-CD2$ mAb (fig. 3C). Costimulation mediated by EFNB3Rs
was at a modcrately lower level than that mediated by the classical costimulatory moiccule
CD28. Anti-CD3 (at a suboptimal concentration) or EfNB3-fc (at an optimal concentration)
alone caused low level or no T-cell proliferation, respectively (last two colurnns of fig. 3C).
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUANG ‘‘u 94
The response of CD4 and CD8 ceils to EFNB3 costimulation was similar (Fig. 3D).
Interestingly, the costimulation via EFNB3R was insensitive to cyclosporin A (CyA). As
shown in Fig. 3E, CyA, which inhibits Ca2 flux-dependent T-cell activation (33, 34), could
effectively suppress ionomycin and PMA-induced 1-celi proliferation but failed to do so for
T ceils activated by PMA plus solid-phase anti-CD28 or PMA plus solid-phase EFNB3. This
finding suggests that CD28 and EFNB3R costimulation both utilize the Ca2tindependent
pathway. Next, we assessed whether the EFNB3 can augment anti-CD28 costimulation in the
presence of anti-CD3. At optimal CD2$ concentration (10 tg/ml for coating), solid-phase
EFNB3 had no additional effect (Fig. 3F). However, at suboptimal anti-CD28 concentration
(5 or 2.5 tg/ml), EFNB3 could moderately enhance the costimulation. This finding suggests
again that CD28 and EFNB3R do flot employ two totally separate pathways.
EfNB3 is known to interact with three Eph receptors, i.e. EphA4, EphB3, and EphB4 (35—
37). We investigated which of these mediated EFNB3-triggered costimulation. Soluble
EphA4, EphB3, or EphB4 alone (3 jig/ml) or in combination were added to MLR, and
thymidine uptake was measured 5 days later. As shown in Fig. 3G, EphA4 and EphB4, but
not EphB3, was able to suppress MLR, suggesting the possible involvement of the former
two in the EFNB3-triggered costimulation.
The expression of certain activation markers on T ceils after EFNB3 costimulation was then
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assessed. T ceils were stimuiated with solid-phase anti-CD3 alone (at a suboptimal amount)
or solid-phase anti-CD3 plus EfNB3-Fc (at an optimal amount). As shown in fig. 4, anti
CD3 alone (shaded area) was unable to up-regulate the activation markers exarnined, i.e.
CD25, CD44, CD54, and CD69. After combined stimulation with anti-CD3 and EFNB3-fc,
CD69 was significantly up-regulated and CD54 was moderately increased, although CD25
and CD44 were not. In contrast, ail of these markers were drastically up-regulated when T
celis were costimulated by solid-phase anti-CD28.
These resuits indicate that EFNB3Rs can enhance T-cell activation to TCR stimulation, but
such enhancement seems qualitatively different from that of CD28.
EFNB3 Enhances Lyrnphokine Production and CTL Activity
We next examined the effect of EFNB3 on T-cell effector functions, such as iymphokine
production and CTL activity. Again, T celis were stimulated with solid-phase anti-CD3 alone
(at a suboptimal amount) or in combination with EfNB3-fc or anti-CD28 (both at optimal
amounts and on solid-phase). NHIgG was used as a negative control for EFNB3-fc. Three
representative lymphokines, IL-2, IL-4, and IfN-y, were measured from day 1 to day 3 afier
stimulation (fig. 5A). Anti-CD3 with or without NHIgG (i.e. PBS) did flot trigger
lymphokine production. Anti-CD28 costirnulation drastically induced IL-2, IL-4, and IfN-y,
as expected. EFNB3-fc led IfN- y production to a level comparable with but moderately
lower than that caused by anti-CD28 costimulation but did not stirnulate IL-4 and IL-2
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production. The lack of IL-2 and IL-4 production after EFNB3 costimulation was flot caused
by a shift of secretion kinetics, because no production of IL-2 or IL-4 was observed at any
time between days 1 and 3 after culture. This resuit demonstrates that EFNB3 and anti-CD28
costirnulation have qualitative differences.
When rnixed lymphocyte reaction was elicited in EFNB3-Fc-coated wells, CTL
development was greatly enhanced (F ig. 5B), whereas control normal human IgG had no
such effect. This finding indicates that EFNB3 costimulation positively regulates an
important effector function of T celis, i.e. CTL activity.
Signating Events in T ceÏts Stintîtlated by EfNB3
To understand the rnechanisms of EFNB3 costimulation, we first examined the transiocation
of EFNB3Rs and TCR on the T-cell surface and their relationship to membrane lipid rafts
immediately after TCR-crosslinking (Fig. 6). TCR was crosslinked by biotinytated anti-CD3
followed by goat anti-hamster IgG. The TCR complex was stained by streptavidin-Alexa
Fluor 594 in red; EFNB3Rs, by EFNB3-Fc followed by anti-human IgG-Alexa Fluor 488 in
green; the lipid rafts in the T-cell membrane, by cholera toxin (CT)-Alexa Fluor 594 in red.
In resting T cells, rafts, TCR, and EFNB3Rs were evenly distributed throughout the celi
surface (0 mm). After 10-min crosslmnking with anti-CD3, TCR rapidly polarized and formed
a cap in one end of the celi. EFNB3Rs also congregated, and they co-localized with TCR (Fig.
6A). After CD3 crosslinking, the rafis underwent congregation and formed caps as well.
EFNB3Rs translocated into the rafi caps (Fig. 6B). This indicated that the TCR complex (as
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUANG u 97
detected by anti-CD3), EfNB3Rs (as detected by EfNB2-Fc), and the raft (as detected by
CT) ail clumped together. This provides a morphological base for EFNB3Rs to enhance TCR
signaling, because now both TCR and EFNB3Rs are closely associated and located in
aggregated rafis, and their respective signaling pathways can interact closely.
In EfNB3-fc-costimulated T celis, we examined MAPK activity, which is modulated in
other ceti types when sornc Eph kinases are activated (38—41). As shown in Fig. 7A, a
combination of solid-phase EFNB3-fc and suboptimal anti-CD3 stimulation for 2 h led to
increased p38 MAPK and p44142 MAPK phosphorylation, a sign of their activation, whereas
anti-CD3 at suboptimal concentration had littie effect, according to immunoblotting. The
membranes were reprobed with anti-p38 MAPK Ab and anti-p44/42 MAPK Ah, respectively.
Total p38 MAPK and p44142 MAPK protein levels were similar with various treatments.
Therefore, these MAPKs were activated after EFNB3R-crosslinking. To test whether such
MAPK activation was relevant and necessaiy in EFNB3 costimulation, we used p38 and
p44142 MAPK-specific inhibitors (SB203580 and PD98059, respectively) to treat T cells
costimulated by EFNB3. Both inhibitors, but not their nonfunctional structural analogue
(SB202474), inhibited EFN33R costirnulation in terms ofproliferation (fig. 7B), indicating
that p38 and p44142 MAPK activation is an integral and necessary part of the EFNB3R
signaling pathway.
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DISCUSSION
We have reported that EfNB3 and EFNB3Rs were expressed in T celis and
monocytes/macrophages. T celis costimulated by solid-phase EfNB3-Fc in the presence of
suboptimal anti-CD3 showed enhanced proliferation and CTL activity, production of IFN- y
but flot IL-2, and expression of certain T-cell activation markers, such as CD69. Upon TCR
activation, EfNB3Rs translocated into the raft caps, to which TCR also congregated. Further
downstream, MAPK activity was enhanced by EfNB3-Fc costimulation. These resuits
suggest that EFNB3 and its receptors play important roles in T-cell activation and function.
The inherent difficulty in studying the receptors and functions of EFNs is that each of them
binds to multiple Eph family members. In the case of EFNB3, it is known to interact with
EphA4 (35), EphB3 (36), and EphB/4 (37), and its interaction with additional Eph members
is also possible. We attempted to identify the receptors mediating the ligation of EFNB3.
Soluble EphA4, EphB3, and EphB4 were added to MLR. EphA4 and EphB4, but not EphB3,
were able to partially inhibit the T-cell proliferation. This suggests that the former two might
mediate the effect ofEFNB3. However, as Ephs and EFNs are capable oftwo-way signaling,
and the EphA4 and EphB4 can potentially interact with EFNs in addition to EfNB3, we
cannot exciude the possibility that the observed inhibitory effect is due to the binding of
EphA4 and EphB4 to certain EFNs (including EFNB3), which transduce negative signaIs
into T celis. Therefore, the receptors responsible for the binding or functions of EFNB3
cannot be conclusively pinpointed until specific mAbs to (and conditional gene knockout
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mice of) each and every Eph (especially EphBs) become available. However, our study is
significant, because the cffect of EFNB3 detected here reflects combinatory functions of ail
receptors triggered by EFNB3, and this is perhaps a true picture of what EfNB3 can achieve
in vivo.
Although the EFNB3 signal was initially flot found in the spleen by Northem blotting (42),
we demonstrated that spleen white pulp expressed EFNB3 mRNA according to in situ
hybridization, and this result was supported by detection ofEFNB3 expression on T celis ami
monocytes/macrophages at the protein level by flow cytometry. The discrepancy between the
previous report and our cunent findings is probably because of the sensitivity of the tests
employed.
Because EfNB3 is expressed on T cells and monocytes/macrophages implies that ail these
celis can enhance responsiveness or reduce the response threshold of EFNB3R T cells to
antigens. This fact might explain the advantage for T cells to be activated in lymphoid organs
where leukocytes are tightly packed. Although costimulation from antigen-presenting celis
to T celis is well studied, we now can understand that the signaling between T-cells is equally
important for T-cell activation. A typicai proof of this concept can be found in any T-cell
culture system, in which minimal ceil density is normally required for optimal T-cell
activation. Although autocrine is often quoted as a reason for such a requirement, interaction
through ceil-surface receptors ami ligands on the T ceils is likely a more fundamental
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mechanism. Recently, Wang et al. (43) have demonstrated that LIGHT, which is a ce!!-
surface !igand belonging to the tumor necrosis factor fami!y member and is predominantly
expressed on T celis, can stimulate T-ce!! activation both in vivo and in vitro through its
receptor HveA on T cetts. We have shown that in pure T-cell culture, the interaction between
Eph36 and its T-ce!l surface ligand can enhance T-cel! response to TCR stimu!ation (20).
The expression ofboth EFNB3 and EfNB3R on T ce!!s and the effect ofEFNB3 on T-cel!s
costimu!ation, as documented in this study, suggests the possibi!ity that these two molecules
are also invo!ved in T-celI/T-cetl cooperation.
We compared T-cell costimulations mediated by CD28 and EFNB3R. The former induced
vigorous production of IL-2, IL-4, and IfN-y, but the !atter on!y triggered IFN-y secretion,
showing a qua!itative difference. T ceils can be activated experimentally through Ca2-
dependent or -independent pathways; the former but flot the latter is sensitive to CyA
inhibition (33, 34). CD28 costimulation in the presence ofPKC activator, PMA, uti!izes the
Ca2-independent pathway and is resistant to CyA (33, 34). In the same mode!, EFNB3R
costirnulation was also resistant to CyA, suggesting that it also activates the Ca2-
independent pathway. When anti-CD2$ was used at suboptima! but not optimal
concentrations, EFNB3 was able to moderately further enhance the T-ceIl proliferation,
suggesting a certain overlap between CD28 and EFNB3R functions. Taken together, these
data show that the signa!ing pathways of CD28 and EFNB3R are distinct but flot tota!ly
separated.
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A recent study showed that plasma membrane compartmentalization plays an essential role
in T-ce!! activation and costimulation. On the T-ce!! membrane, detergent-inso!uble
glycolipid-enriched rafts contain proteins, such as Src kinases that arc highly re!evant for T
celi signaling (44). Strong TCR ligation induces the association of TCR and the rafis, and this
association is correlated with TCR signaling and T-ceÏl activation (40). In our case, EFNB3R
migrated into the rafts after TCR crosslinking (as seen in Fig. 6) by anti-CD3. Therefore, it is
possible that EfNB3Rs works in concert with TCR: TCR crosslinking leads to raft
reorganization, EfNB3R congregates into the capped rafts where it co-localizes with TCR,
and the EfNB3R signaling pathway interacts with that of TCR and enhances the latter.
For proper T-celL activation, Ras and Rac signaling pathways need to be mobilized. Ras
activation leads to activation of p44/42 MAPK kinases, which, in tum, resuits in the synthesis
and activation of various transcription factors. On the other hand, activation of Rac and
Cdc42 small G proteins elicits p38 MAPK activation, which is essential for cytoskeleton
reorganization. Such reorganization is now known to be pivotai for T-ccll signa!ing (40). We
have found that the activities of both p44142 and p38 MAPK are enhanced in the presence of
EFNB3 costimulation, and this is consistent with the roies of these MAPK in T-cell
activation. Recently, it has been reported that EphB2 activation resuits in the inhibition of
p44/42 MAPK in neuronal ceils (45), and that EphA activation leads to inhibition of this
kinase in several cdl !ines ofendothelia! and epithelial origin (41). Obviously, these reports
deal with ce!! types that are different from those in our study, but the consequence is different
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as we!!.
Our study demonstrates the role of EFNB3 in regulating T-ce!! function. Similar functions
were found with EFNB 1 and EFNB2 (data flot shown), suggesting that these molecu!es have
overlapping but essential functions in T-ccll activation. These findings represent an initia!
step toward understanding the biologica! significance of ephrins and Ephs in the immune
system.
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figure J. in situ hybridization offFNB3
Antisense or sense probes were hybndized with BALB/c spleen sections. Liver sections
served as negative controls. Original magnification: 10 X.
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figure 2. flow cytometiy analysis oJEfNB3 and EfNB3R expression on leukocytes
A and B: Two-color ftow cytometly was used to determine the expression of EFNB3
(detected with anti-EfNB3 Ab) or EFNB3R (detected with EfNB3-fc) on T ceils, B ceils
and monocytes/macrophages. T celis were stained with anti-CD3; B celis, with anti-B220;
and monocytes/macrophages, with F4180. For T ceils analysis, the spleen ceils were
cultured in medium with (Activated) or without (Resting) solid-phase anti-CD3 for 24 h.
For B celis and monocytes/macrophages analysis, they were assayed after 24-h culture in
plain medium. C. One-color flow cytometry was used to measure the expression ofEFNB3
(detected with anti-EFNB3) and EFNB3R (detected with EFNB3-Fc) on magnetic bead
purified CD4 and CD8 cells (about 95% pure) after 24-h culture in medium.
The percentages of positive celis (areas under the solid curves subtracted by shaded areas
[normal rabbit IgG or Norman human IgG as controls]) are indicated. The experiment was
performed more than three times and was reproducible. Results from a representative
experiment are shown.
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figure 3. Sotid phase EfNB3-Fc enÏtances T-cellprolferation upon TCR stimulation
The affix “anti” used in conjunction with rnAbs is simplified as “Œ” in this and ail the other
figures of this article. Ail the concentrations indicated in the figure legends represent those
employed during the coating procedure, unless indicated otherwise. Normal human IgG
(NHIgG) served as a control for EFNB3-Fc. BALB/c T ceils were cultured in wells coated
with (A) a suboptimal amount of anti-CD3 (0.8 jig/ml) and different amounts of EFNB3-
Fc; (B) a fixed optimal amount of EFNB3-fc (10 tg/m1) and different amounts of anti
CD3; or (C) a suboptimal amount of anti-CD3 (0.8 jtg/ml) along with optimal amounts of
anti-CD28 or EFNB3-Fc (both at 10 jig/rnl). (D) Magnetic bead-purified spleen CD4 or
CD8 ceils were cultured in wells coated with suboptimal amount of anti-CD3 (0.8 ig/ml),
and optimal amount of anti-CD28 or EfNB3-Fc (both at 10 ig/m1). (E) T cells were
cultured in weÏl coated with anti-CD28 (10 cg/rnl) or EFNB3 (10 tg/ml); PMA (20 ng/ml),
inomycin (1 mg/ml), and CyA (250 nM) were added to the culture solution, as indicated.
(F) T celis were cultured in wells coated with anti-CD3 (0.8 tg/ml), EFNB3 (10 ig/ml),
and various concentrations of anti-CD28, as indicated. (G) Mitomycin C-treated BALB/c
spleen celis (4x105 cells/200jil/well) were used as stimulators, and C57BL/6 spleen cells
(4x105 cells/200pJ/well) were used as responders in MLR; the cells were cultured in the
presence of EphA4 (3 tg/ml), EphB3 (3 jiglml), EphB4 (3 .ig/ml), ail of the three Ephs
(Mix; at 3 tg/mi each), NHIgG (3 jig/ml), or no additional reagents (Nil).
The ceils were cultured for 48 h (A-F), or 120 h (G), and their 3H-thymidine uptake in the
last 16 h was measured. The experiments were performed more than three times and were
reproducible. Means ± SD of triplicate samples from a representative experiment are
shown.
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Fig. 4
With cCD3 and EFNB3 costimulation
figure 4. Activation marker expression ofEFNB3-fc-costimutated T ceils
BALB/c T celis were cultured in wells coated with anti-CD3 mAb (0.8 ig/m1) plus
EFNB3-Fc or anti-CD28 (both at 10 tg/m1). Their activation marker expression at 24 h was
assessed by 2-color flow cytometry, using anti-Thyl.2-PE for T-cell gating, and anti-CD25-
FITC, anti-CD44-FITC, anti-CD54-FITC, and anti-CD69-FITC for activation markers.
Percentages represent activation marker-positive celis among Thyl.2-positive celis in the
gated regions after deducting background staining (isotypic Ab controls for mAb against
activation markers, shaded area) of the ceils. The experiment was performed more than
three times and was reproducible. Resuits from a representative experiment are shown.
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Figure 5. EFNB3-Fc enhances T-cett effectorfiinction
A. Solid phase EfN33-Fc modulates Ïymphokine production by anti-cD3-stimulated Tcells
Mouse spleen T cefls were stimulated with solid phase EfNB3-Fc (10 jig/ml) in the
presence of a suboptimal concentration of anti-CD3 (0.8 jig/ml). Anti-CD28 and NHIgG
(both at 10 ig!ml) were used as positive and negative controls, respectively. Some wells
were only coated with anti-CD3, followed by PBS incubation (PB$), and were used as
additional blank controls. The culture supernatants were harvcsted from days 1 to 3, and
lymphokines in the supernatants were measured by ELISA. The experiment was perforrned
more than twice and was reproducible. Means ± SD of duplicate samples from a
representative experiment are shown.
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B. EJjèct ofsoÏidphase EfNB3-Fc on CTL deveÏoprnent
2C mouse spleen ceils were mixed with an equal arnount of mitornycin C-treated BALB/c
mouse spleen cells and seeded in flat-bottorned 24-well plates, which were pre-coated with
EfNB3-Fc or NHIgG (both at 10 tg g/ml), or not coated (Medium). Afier 6 days, CTL
activity in the stirnulated ceils was measured by a standard 4-h 51Cr-release assay, using
P815 ceils as targets. The samples were tested in tnplicate, and means ± SD of the
percentage of target ceil lysis are shown. The experirnents were performed twice with
similar results, and the data of a representative experiment are shown.
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figure 6. Rapid co-ÏocaÏization of EFNB3R with TCR and ra/? caps afier anii-CD3-
crossÏinking
BALB/c spleen T celis were crosslinked with anti-CD3 for O or 10 miii, as indicated. The
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locations of TCR (stained with biotin-anti-CD3 foiiowed by Alexa Fluor 594-streptavidin
in red) (A), EFNB3R (stained with EFNB3-fc foilowed by Alexa 488-anti-human IgG in
green) (A and B), and rafts (stained with Alexa Fluor 594—choiera toxin (CT) in red) (B)
were reveaied by confocai microscopy. Ail experiments were conducted more than 3 tirnes
and were reproducible. Representative resuits are shown.
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Figure 7. Activation ofp38 MAPK andp44/42 MAPK in T celis by solid phase EFNB3-Fc
B. hnmunoblotting oJp38 andp44/42 MAFK
T ceils were added to wells coated with EFNB3-Fc or NHIgG (both at 10 tg/mi) in the
presence of a suboptimai amount of anti-CD3 (0.8 ig/ml). The ceils were harvested after 2
h, and anaiyzed by immunobiotting. Arrows indicate signais of p38 phospho-MAPK and
total p38 MAPK of the same membrane, and signais of p44142 phospho-MAPK and total
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p44/42 MAPK ofthe same membrane. The experiment was performed more than twice and
was reproducible. Results from a representative experiment are shown.
B. p38 and p44/42 inhibitors specifically inhibit EFNB3-Fc-costirnulated T-celÏ
prohferation
T ceils were pre-incubated for 1 h in complete culture medium containing the p38 MAPK
specific inhibitor SB2035$0, the p44/42-specific inhibitor PD9$059, and its non-functional
structural analogue SB202474 (ail at 10 tM), or vehicle (DMSO, dimethyl sulfoxide,
0.1%). The ceils were then transferred to wells coated with EFNB3-Fc (10 cg!ml), anti
CD3 mAb OKT3 (0.8 rg/ml), or both, and cultured for 48 h. 3H-thymidine was added to
the culture for the last 8 h, and thymidine uptake by the cells was measured. The
experiment was performed more than twice and was reproducible. Resuits from a
representative experiment are shown.
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ABSTRACT
Eph kinases are the largest family of receptor tyrosine kinases, and their ligands, ephrins
(EFN), are also celi surface molecules. In this study, we investigated the role of EfNB 1 and
the Ephs it interacts with (collectively called EFNB1R) in mouse T-cell development. In
the thymus, CD8 single positive (SP) and CD4CD8 double positive (DP) celis expressed
high levels ofEFNB1 and EFNB1R, while CD4 SP ceils had moderate expression ofboth.
Soluble EFNB1-Fc in fetal thymus organ culture (FTOC) caused significant subpopulation
ratio skew, with increased CD4 and CD8 SP, and decreased DP percentage, while the
cellularity of the thymus remained constant. Moreover, in EfNB 1 -treated fTOC, CD$ SP
celis had a significantly enhanced proliferation history, followed by CD1 17f, DP, CD25,
and then CD4 SP cells, according to BrdU uptake. In vitro culture of isolated thymocytes
revealed that EFNB1-Fc on solid phase protected thymocytes from anti-CD3-induced
apoptosis, while EFNB 1-fc in solution augmented such apoptosis. The degree of such
protection and enhancing effect on different subpopulations followed the order of their
EFNB1R expression levels. At the molecular level, EFNB1R co-migrated with TCR to
lipid rafts during TCR activation, and EFNBÏR increased TCR signaling strength as
evidenced by enhanced phosphrnylation of LAT and cbl. These observations collectively
suggest the following model: the interaction between endogenous EfNB 1 and EfNB 1 R
promotes thymocyte survival, either during positive selection, or in the post-selection
period at the SP stage; disruption of such interaction by soluble EfNB1-Fc resuits in
differential degree of apoptosis of according to levels of EFNB1R expression;
compensatory proliferation occuned to maintain cellularity homeostasis; the sum of such
dynamic changes is the ratio skew of subpopulations. This study reveals that EfNB 1 and
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EfNB1R are critical in thymocyte development.
INTRODUCTION
Receptors are important celi-surface molecules for communication between ceils and their
environment. Protein tyrosine kinases (PTK) are essentiai components in lymphocyte
signaling pathways. Thus, receptor tyrosine kinases have dual pivotai functions in
iymphocytes. The Eph kinases are the iargest receptor PTK famiiy. According to sequence
homology, Eph kinases are classifled into EphAs (EphAl to EphA9) and EphBs (EphBl to
EphB6) (Ï, http ://cbweb .med.harvard.edu/eph-nomenclature/ceiiletter.html). Ephrins
(EFNs), Iigands of Eph kinases, are ceil surface molecules as well, and can be classified
into A and B subfamiiies. EFNAs (EFNAÏ to EFNA6) are giycosylphosphatidylinositoi
anchored proteins, and bind to EphA members with loose specificity; EfNBs (EFNB 1 to
EFNB3) are transmembrane proteins, and bind to EphBs, again with loose specificity (Ï).
EphA4, an exception, can bind to EFNB2 in addition to EFNA members (2). EFNBs can
aiso function as reciprocal receptors for EphB molecules, and reversely transduce signais
into ceiis (3). Most Eph kinases or EFNs have likely aiready been identified, because
sequences from the human genome project have reveaied 14 Eph entries and 8 EFN entries
(4).
Since Eph kinases and their ligands are ail ceii surface molecules, they can oniy interact
with each other when expressed on adjacent ceils. Not surprisingly, the cleariy
demonstrated function of these receptors and ligands is to controi accurate spatial
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patteming and celi positioning in the central nervous (5, 6) and gastrointestinai (7) systems,
and in angiogenesis (8).
Some of the Eph kinases and their ligands are expressed on immune cells (9-12); limited
knowledge about their function in immune responses is available, and is described as
follows. We have reported previousiy that a kinase-defective Eph family member, EphB6,
is capable of transducing signais into T cells, probably through adaptor moiecules
associated with its intraceliuiar tau (13). Activation ofEphB6 with solid phase anti-EphB6
mAb resuits in Jurkat celi apoptosis (13), or augmentation of normai human T-ceil
responses to Ag stimulation (14). EfNB2 and EfNB3, as well as their receptors, are
expressed on peripheral T ceils. Soiid phase EFNB2 and EfNB3 can augment TCR
stimulation in vitro (15, 16). Some EphA members have been reported to be expressed on
different populations ofthymocytes (17), and some EphAs and EfNAs interfere with T-celi
deveiopment in thymic organ culture (18). EFNA1 can inhibit T-cell chemotaxis (19).
The thymus is the cradle of T cells. Early T-lineage cells in the thymus are usually
described as triple negative (TN, CD3CD4CD8) cells. Through the rearrangement of
TCR, TN cells become immature double positive (DP, CD4CD8) and express a low level
of CD3. After this DP transition, the thymocytes undergo extensive positive and negative
selections to ensure that the mature T cells are functional and self-tolerant. Positive and
negative selection of thymocytes has been reported to occur either in the cortex at the
cortex-medullary junction, or within the medulla (20, 21). After selection, the DP celis
transiently express high levels of CD3-associated TCR to form mature DP ceils, and then
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rapidly differentiate into mature CD4 or CD8 single positive (SP) T cells that express higli
levels ofTCR (22).
Positive and negative selection depends on MHC (23,24), on the concentration of peptide
presented, and on the accessory molecules involved, ah of which are important in
determining the strength of TCR signaling (25-27). However, the late stage of positive
selection and associated post-selection events seems independent of the same peptide/MHC
complexes responsible for the initiation of positive selection (28,29); it is possible that ceils
adjacent to the T cells under selection express certain cell surface-associated molecules that
provide additional signals needed for this stage.
In this study, we investigated the expression of EFNB 1 and its receptors in thymocytes and
its role in modulating T-cell development.
MATERIALS AND METHODS
In situ hybridization
A 534-bp cDNA fragment ofmouse EFNBÏ cDNA from positions 336 to 890 (accession
number U12983) was fetched with PCR from a mouse embryonic tissue cDNA libraiy and
cloned into pGEM-4Z (Invitrogen, San Diego, CA). The resulting construct, pGEM-4Z-
mB Ï, served to transcribe anti-sense probes with SP6 RNA polymerase or to transcribe
sense probes with T7 RNA polymerase, using digoxigenin RNA labeling kits (Roche
Diagnostics, Lavai, Quebec, Canada). In situ hybridization was carried out according to
instructions from the kit manufacturer.
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Generation ofmouse EfNB-fc
The coding sequence of the extracellular domains of mouse EFNB 1 from positions 255 to
803 was cloned in-frame upstream ofthe human IgGi-Fc coding sequence in an expression
vector pCMVhfc. The constructs and pcDNA3 were then transfected into CHO/dhfr celis
with Lipofectarnine. The ceils were cultured in selection medium (OEMEM without
ribonucleosides and deoxyribonucleosides containing 5% dialyzed fCS, 0.01 mM
methotrexate, 0.8 mg/ml G4 18 and 0.1 mg/ml gentamycin). After 2 weeks of culture, stably
transfected clones were handpicked. Fusion proteins were isolated from supernatants by
protein A columns, and verified by N-terminal peptide sequencing (Sheldon Biotechnology
Center, McGill University, Montreal, Quebec, Canada). Generation of EFNB2-Fc and
EFNB3-Fc has been described previously (15, 16).
Fetal thymus rngan cultttre (FTOC)
Thymuses were sterilely isolated from e17 (embiyonic day 17) BALB/c fetuses, and
cultured in fTOC medium at 37°C in 5% C02, as described by DeLuca et al. (30). Briefly,
the isolated thymic lobes were placed on the surface of a white plain Millipore filter
membrane (ISOPORE, 0.4 tM pore size, Bedford, MA), which was supported undemeath
by surgical gelfoam (ETHICON, Somerville, NI) in 24-well plates (Costar, Coming, NY).
Each well contained 0.8 ml culture medium consisting of Dulbeccos MEM, 20% FCS
(Hyclone Laboratories, Logan, UT), streptomycin (100 tg/m1), and penicillin (250 U/rnl).
Non-essential amino acids (0.1 mM), sodium pyruvate (1 mM), 2-mercaptoethanol (20
nM), and 3.4 mg/ml sodium bicarbonate were added to the medium as supplements.
Various recombinant proteins, antibodies or chemical reagents were also included in the
medium as indicated in the different experiments. Half of the medium was replaced every
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2-3 days until harvesting.
FÏow cytometiy
For the measurement of EFNB and EFNB receptor expression in different thymocyte
subpopulations and of the percentage of different thymocyte subpopulations, thymocytes
from fresh e 17 thymuses or from FTOC were stained with EFNB-Fc/goat anti-human IgG
FITC, or with goat anti-EFNB (R&D, Minneapolis, MN), followed by donkey anti-goat
IgG-FITC (Cedarlane, Hornby, Ontario, Canada); anti-CD4-biotinlStreptavidin-Quantum
Red and anti-CD8-PE, anti-CD25-PE, or anti-CDYÏ7-PE (PharMingen, San Diego, CA)
were employed to gate different thymic subpopulations. To assess celi proliferation, anti
BrdU-Alexa 48$ (Molecular Probes, Eugene, OR) was used for staining. Annexin V-FITC
(PharMingen) was used to stain apoptotic cells.
Coifocat micmscopy
Five million aduit BALB/c thymocytes were reacted on ice for 30 min with 5 ig of
EFNB 1 -Fc and 1 jig each of biotinylated anti-CD3 (clone 2C 11, hamster mAb) and anti
CD4. After washing, the celis were incubated with goat anti-hamster IgG (5 jig/sample) for
30 min on ice. The celis were washed with coid PBS and transferred to warrn PBS to start
the crosslinking process at 37°C. The celis were then immediately fixed with 3.7%
formalin. For TCR and EFNB1R staining, respectively, the celis were reacted with
streptavidin-Alexa Fluor 594 (1 ig/sample) and goat anti-human IgG-Alexa Fluor 488 (1
jig/106 celis) on ice for 30 min. For raft and EFNB1R staining, the procedure was similar as
described above, but choiera toxin-Alexa Fluor 594 (0.5 jig/sample) was used in place of
streptavidin-Alexa Fluor 594. The Alexa Fluor-conjugated reagents were from Molecular
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Probes. The reaction volume of all above staining and cross-Iinking procedures was aiways
100 tl. The siides were examined under a confocal microscope.
Immunoblotting
Thymocytes (10x106 cells/sample) from adult BALB!c mice were incubated with anti-CD3
(clone 2C11, ljig/ml) and EFNB1-Fc or NHIgG (5 ig/ml) on ice for 1 h, followed by one
wash in cold PB$. Anti-hamster IgG and anti-human IgG (both at 1 ig!ml) were then
added and the ceils were incubated for 30 min on ice; crosslinking (2.5 mm) took place by
transferring the cells to 3 7°C. The remainder of the procedure was detailed in our previous
publication (31). Briefly, the harvested cells were washed and lysed in lysis buffer for 10
min. For LAT detection, the cleared lysates were resolved in 10% SDS-PAGE with 50 tg
protein/lane, and then blotted onto polyvinylidene difluoride membranes; phosphorylated
LAT was detected with polyclonal anti-phospho-LAT (Ceil Signaling, Mississauga,
Ontario, Canada); total LAT was assayed with anti-LAI mAb (Clone 45, BD Transduction
Laboratory, Mississauga, Ontario, Canada). For cbl detection, cbl in the lysates (200 jig
protein/sample) was first immunoprecipitated with rabbit anti-cbl Ab (Santa Cruz Biotech,
Santa Cruz, CA); after 8% SDS-PAGE and blotting, phosphorylated cbl was detected with
anti-phosphoprotein mAb (PY2O, BD Transduction Laboratory), and total cbl was tested
with anti-cbl mAb (Clone 17, BD Transduction Laboratory). SignaIs were revealed by
enhanced chemiluminescence.
RESULTS
EFNBJ and EfNBÏR expression in the thymus
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Expression of EFNB 1 mRNA in the aduit thymus was detected by in situ hybridization. As
shown in FigurelA, the cortex was highly positive; sparse signais were present in the
medulia; the subcapsule region was negative.
Expression of EFNB 1 and its receptor(s) on various thymocyte subpopulations at the
protein level was then investigated by flow cytometry. The aduit and e17 thymus had
similar expression pattems, and representative histograms of e 17 thymocytes are shown in
Figure 13. For EFNB 1 (upper row of Figure lB), CD8 $P and CD4CD8 DP ceils had the
highest expression at 29.9% and 29.4%, respectively; the expression on DN (double
negative) ceils was at a lower level (13.5%); CD4 SP celis had the lowest expression
(6.2%). In comparison, another EFNB family member, EFNB3 (upper row of Figure lB),
had iow expression in ail these subpopulations (3.3% in DN, 1.2% in DP 2.3% in CD4 $
and 7.4% in CD8 SP). Such differential expression leveis ofEFNB1 versus EFNB3 suggest
that the former plays a more important role in T-cell development in the thymus.
EFNB1 promiscuously binds to multiple EphB family members (2, 32). The receptor
binding of EFNB 1 to thymocytes was assessed by EFNB 1 -Fc staining; such binding
revealed the interaction of EFNB1 with the ensemble of all its receptors, which are
collectively referred to as EFNB ÏR, on thymocytes. As shown in the lower row of Figure
lB, EFNBR expression was highest in CD8 $P (40.7%), foiiowed by DP (3 1.5%) and CD4
SP (8.5%); DN had no detectable expression (0%). In contrast, EFNB3R expression (lower
row of Figure lB), as measured by EFNB3-Fc binding, was low in most subpopuiations
(0% in DN, 3.2% in DP, and 0.3% in CD4 SP), with the exception of CD8 $P (11.4%),
suggesting a more prominent role of EFNB 1 R than that of EFNB3R in thymic T-cell
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development.
The high percentage of DC$ and DP in their expression of EFNB1 ami EFNB1R, as
revealed in this section, raises an intriguing possibility that these two subpopulations
preferentially depend on EFNB1 and EfNB1R for certain developmental processes.
Soluble EfNB] distttrbs subpopulation ratios in fTOC
FTOC was employed to investigate the role of EFNBI and EFNBIR interaction in
thymocyte development in a setting relatively close to a physiological condition; various
recombinant proteins were added to the culture. We first verified whether EfNB 1 -Fc could
enter the thymus easily. FTOC was conducted in the presence of EFNB 1-fc (10 ig/ml) for
24h; thymocytes were flushed out, extensively washed, and then reacted with PE
conjugated anti-hurnan IgG; 31.3% of the thymocytes were positive for EfNB1R (right
panel, f igure 2A), and this percentage was comparable to that of fresh thymocytes stained
with EfNBY-Fc followed by PE-conjugated anti-human IgG (left panel, f igure 2A). This
indicates that EfNB 1-fc can effectively enter the fTOC within 24 h.
Next, the effect ofEfNBs on fTOC was investigated. After 5-day or lO-day culture in the
presence ofEfNBl-fc, EFNB2-Fc, EfNB3-fc or NHIgG (ail at 10 ig/m1), the CD4 and
CD$ expression of celis from fTOC was assessed by flow cytometry. As shown in figure
23, afler 10 -day culture, in comparison with thymocytes from NHIgG-treated fTOC, there
was a consistent and obvious decrease of DP (from 69.9% to 37.2%), but an increase of
CD4 SP (from 16.0% to 30.1%) and CD$ SP (from 5.4% to 10.9%) percentage in the
presence of EFNBÏ-fc. On the other hand, EfNB2-fc and EfNB3-Fc did not drastically
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alter the ratios of these subpopulations. Therefore, for the rest of this study, our attention
was focused on EFNBI and EFNB1R; EFNB3-Fc was used for comparison only. At an
earlier stage offTOC, the change of ceil population was less drastic than that ofday 10, but
the tendency was consistent with that of the lO-day culture. For example, on FTOC day 5
(Figure 2C), there was a decrease of DP ccli population (from 88.4% to 68.9%) and an
increase ofCD8 SP celis (from 5.7% to 10.7%) and CD4 SP celis (from 3.2% to 6.3%) in
EFNB 1 -Fc-treated thymus, compared with NHIgG-treated thymus. The effect of another
control EFNB3-Fc was similar to NHIgG, except it caused some increase of CD4 SP
population. The effect ofEFNB3 in this system is not in the scope of this paper.
The ratios of thymocyte subpopulations were determined by a combination of factors, such
as proliferation, apoptosis, and extinguishing of CD4 or CD8 expression on D? ceils. To
gain insight into the reasons for the observed ratio disturbance in EFNB1-Fc-treated FTOC,
we measured the proliferation history of each subpopulation by BrdU uptake during the 10-
day culture period (Figure 3A). There was a significant increase of BrdU-positive ccli
percentage in CD8 SP (from 4.4% to 89.7%), CD1Y7 ceils (from 31.7% to 63.2%), DN
(from 31.7% to 61.3%), CD25 cells (from 17.4% to 53.6%), DP (from 11.3% to 54.5%) and
CD4 S? (from 10.2% to 48.0%) subpopulations in EFNB1-Fc-treated FTOC cornpared with
that of NHIgG-treated FTOC. The increase is most significant in CD$ cells. EFNB3-Fc
treatment increased the BrdU-positive percentage in these subpopulations to a much less
extent. This suggests that in the presence of soluble EFNB 1 -Fc, thymocytes in FTOC have
high rates of turnover.
We next enumerated apoptotic celis on day 10 of FTOC, according to Annexin V staining
FACULTÉ DES ÉTUDES SuPÉRIEu1S UNIVERSITÉ DE MONTRÉAL GUANG ‘u 130
(Figure 3B). DP CD4 SP and CD8 SP celis from FTOC treated with NHIgG had a similar
percentage of apoptotic celis, in the range of 13.3% to 20.0%. EFNBY treatment only
moderately increased the percentage of apoptotic ceils in DP and CD4 SP celis to 28.5 and
18.8%, respectively, whule CD8 SP celis exhibited more apoptosis (43.2%) than other
subpopulations. On the other hand, EFNB3-fc, which was used for comparison, had no
apparent effect. It should be noted that the efficiency of apoptotic ce!! remova! in FTOC
was flot known; sucli cross-sectional assessment of apoptotic ceils on a given day miglit
on!y reflect the apoptosis in excess of the apoptotic celi remova! capacity in the thymus. If
we assume apoptotic celis in different subpopu!ations are eliminated at similar rates, it
raises an intriguing possibi!ity that CD8 SPin the presence of so!uble EFNB1-Fc undergoes
excessive apoptosis; such a high rate lias significantly surpassed the removal rate; as a
consequence, Annexin V positive cel!s in the CD8 SP subpopulation has an obvious
increase.
Cellularity in fTOC after EfNB1-Fc treatment was investigated after 5, 10 or 12 days of
fTOC, and the resu!ts (Figure 3C) revea!ed that the numbers were similar in EfNBÏ-fc-,
EFNB3-Fc- or NHIgG-treated cu!tures. Therefore, it appears that a homeostatic mechanism
keeps the thymie cellularity constant, despite drastic proliferation and apoptosis in some
subpopulations under the influence of so!ub!e EfNB 1-fc
EFNB1R crosstbtkbtg promotes thyinocyte survivat
It is difficu!t to assess the actual rates of apoptosis of thymocyte subpopu!ations in fTOC,
even if Annexin V positive celis is measured at a given time, because apoptotic ceils are
constant!y removed, and the efficiency of this process cannot be accurate!y determined. To
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understand how soluble EFNB 1 caused the ratio skew of different subpopulations, we
investigated its effect on isolated e17 fetal thymocytes in the presence of a high dose of
solid phase anti-CD3 (10 .tg/ml during coating), which enhanced thymocyte apoptosis.
Apoptosis of DP, CD4 SP and CD$ SP thymocytes was significantly reduced in the
presence of soÏid phase EfNB1-Fc (top row, Figure 4A), in comparison to that in the
presence of solid phase NHIgG (bottom row); interestingly, the magnitude of apoptosis
reduction in different subpopulations (CD8 SP a 45.3% decrease from 47.5% to 2.3%; DP
celis, a 23.4% decrease from 39.7% to 16.3%; CD4 SP, a 8.2% decrease from 20.5% to
12.3%) followed the order oftheir EFNBRY expression levels, i.e., CD8, DP and then CD4
(from the most to the least decrease of apoptosis; also from the highest to the lowest
EFNBÏR expression). On the other hand, the effect of EFNB3-Fc on Annexin V expression
was much less drastic (middle row, Figure 4A). This suggests that EFNBÏR transmits
survival signais into these celis. If this is the case, a similar protective effect should occur
when EFNB1R on thymocytes receive stimulation from neighboring EFNB i-expressing
celis, including other thymocytes; further, blocking such interactions should lead to
enhanced apoptosis. This prediction was assessed in a model of isolated e17 fetal
thymocytes stimulated with a low dose of solid phase anti-CD3 (2j.ig/ml during coating) to
induce low levels of apoptosis. Soluble NHIgG was added to the culture as a control for
EFNBs-Fc to measure apoptosis produced by anti-CD3-induced alone (in the range
between 16.4% and 20.5%, bottom row, Figure 4B). When soluble EFNBÏ-Fc was added to
the culture, significant apoptosis occurred in CD$ $P celis ta 32.6% increase from 20.5% to
53.1%), followed by DP (a 10.1% increase from 16.4% to 26.5%), while the degree ofCD4
SP apoptosis remained unchanged (a 0.4% increase from 27.1% to 27.5%). It is interesting
to note that, again, the degree of apoptosis of each subpopulation was correlated to their
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respective EFNB1R expression level. Soluble EFNB3-fc, which was used for comparison,
caused moderately increased apoptosis in CD8 SP and DP but not CD4 SP celis (second
row, Figure 4B; CD8 SP, 12.1% increase from 20.5% to 32.6%; DP, 6.4% increase from
16.4% to 22.8%; CD4 SP, basically unchanged with 1% increase from 27.1% to 28.1%),
compared to NHIgG. These resuits suggest that the exogenous soluble EFNB 1 -Fc interferes
with the anti-apoptotic effect of the endogenous EFNB1 and EFNB1R interaction. The
resuits of this section have raised an intriguing possibility that the obseiwed subpopulation
skew in EFNBI-Fc-treated FTOC was driven by excessive apoptosis of CD8 SP and DP
cefls, as a result ofthe blockage ofthe survival signals initiated by endogenous EFNB1.
Signaling events in thyinocytes stimuÏated by EfNB]
To understand the mechanism of the survival signaIs transmitted via EFNB IR, we first
examined EFNB YR and TCR transiocation on the ceIl surface, and the relationship between
EFNBYR and membrane lipid rafts immediately after TCR-crosslinking, which was
achieved with coating the thymocytes with biotinylated anti-CD3 mAb (hamster IgG) and
then crosslinking the mAb with goat anti-hamster IgG. The TCR complex was stained by
streptavidin-Alexa Fluor 594 in red, which reacted with biotinylated anti-CD3; EfNBYR,
by EFNB1-Fc foflowed by anti-human IgG-Alexa Fluor 488 in green; the Iipid rafts in the
T-cell membrane, by choiera toxin-Alexa Fluor 594 in red. Raft, TCR and EFNB1 were
evenly distributed throughout the ceil surface in resting celis (0 mm, Figure 5). After 10-
min crosslinking with anti-CD3, TCR rapidly polarized and formed a cap in one end ofthe
celi. EFNB1R also congregated, and co-localized with TCR. Such co-capping lasted more
than 20 min (data not shown). Control human IgG (in place of EFNBÏ-Fc) followed by
anti-human IgG-Alexa Fluor 488 detected no signals in these ceils (data not shown). After
FACULTÉ DES ÉTUDES SuPÉRIEuiS UNIVERSITÉ DE MONTRÉAL GUANGYU 133
the CD3 cross!inking, raft also underwent congregation and forrned caps, and EFNBIR co
localized with raft caps. Taken together, these data indicate that TCR and EFNB1R both
congregate to a raft cap on the celi surface after TCR-crosslinking. This provides a
morphological base for EFNB 1 to enhance TCR signaling, since now both TCR and
EFNB1R are closeÏy associated and located in aggregated rafts, which are scaffolds
accommodating many signaling molecules. Perhaps such enhanced TCR signaling provided
surviva! signais to subpopulations ofthymocytes, notably DP and CD8 SP ceils.
We next examined a couple of signaling molecules involved in T-ce!! activation. LAT
(linker for activation of T ce!ls) is a transmembrane protein, which is phosphorylated after
T-cell activation, and its phosphorylation enables it to recruit additional signaling
mo!ecuies (33). We found that in thymocytes, EFNB1R-crosslinking resulted in augmented
LAT phosphorylation over that caused by TCR-crosslinking (Figure 6A), suggesting that
EFNBYR could enhance the LAT function. Cbl is an adaptor rnolecu!e, and also an E3
ubiquitin ligase; both of these functions are important for T celi activation (34, 35). We
demonstrated that tyrosine phosphoiylation of cbl after EFNB 1 R- and CD3-cross!inking
was increased compared with CD3 cross!inking a!one (Figure 6B), raising the possibility
that such phosphory!ation a!iows cbl to interact with SH2 domains of other signaling
moiecules.
DISCUSSION
In this study, we showed that EFNB1 and EFNB1R were expressed differentially on
thymocyte subpopulations, with CD8 and DP ce!ls expressing high levels ofboth the ligand
and its receptors; EFNBÏ deiivered survival signais via EFNB1R to the thymocytes, and
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high EFNB1R-expressing celis seemed to benefit most the effect; FTOC in the presence of
soluble EFNB 1 -Fc had significant subpopulation ratio skew, possibly the resuit of apoptosis
and compensatoiy proliferation of different subpopulations. At the molecular level,
EFNB1R migrated to rafts and co-localized with TCR, when TCR was activated; EfNBÏ
crosslinking augmented TCR downstream signaling events such as LAT and cbl
phosphorylation.
When soluble EFNB1-Fc was present in FTOC, it caused a drastic reduction of DP ceils,
and an increase of CD4 and CD2 SP celis. The changes were in the percentage of each
subpopulation, as the total cellularity remained similar in the EFNB- versus NHIgG-treated
thymus. Four findings provide dues to the mechanisrns of such changes: 1) accelerated
thymocyte proliferation according to BrdU incorporation during the lO-day FTOC in the
presence of EFNB 1-Fc; 2) increased thymocyte apoptosis according to isolated thyrnocyte
culture in the presence of soluble EFNB 1; 3) protection of thymocyte apoptosis by EFNB 1
on solid phase according to isolated thymocyte culture; 4) the degree of such apoptosis
protection and induction was correlated to EFNBÏR expression levels on different
subpopulations. Based on these finding, two models could be formulated.
In the flrst model, soluble EfNB1 enters the thymus, and drives the proliferation of
thymocyte subpolulations; such proliferation, in turn, triggers a homeostatic mechanism,
which dictates that the total cellularity of a thymus should remain constant; as a resuit,
excess thyrnocytes werc eliminated by apoptosis; the imbalance between proliferation and
apoptosis was manifested as altered ratios of subpopulations in FTOC. It is interesting that
CD8 SP cells, the subpopulation with the highest EFNB1R expression, has a history ofthe
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most proliferation, while CD4 SP celis with the lowest EfNBYR expression had a history of
the least proliferation. Such a correlation can suggest that proliferation is the primary
driving force for the observed subpopulations skew in FTOC in the presence of EFNB 1.
However, we found no evidence that soluble EFNBÏ-Fc could stirnulate isolated
thymocytes to proliferate in vitro, in the absence or presence of TCR stimulation (data flot
shown). The validity ofthis mode! is thus very questionable.
In the second model, the soluble EFNB1-Fc causes apoptosis of thymocytes; the
consequent loss of thymocytes in fTOC triggers compensatory proliferation to maintain
horneostasis; the imbalance of apoptosis and proliferation resuits in subpopulation ratio
skew. In support of this mode!, solid phase EFNB 1 inhibited thymocyte apoptosis in vitro;
soluble EfNB1-fc caused increased apoptosis ofisolated thymocytes in vitro, probably due
to its interference to the endogenous EFNB1 and EFNB1R interaction between thymocytes;
we a!so found that the subpopulations expressing high EFNB1R on the surface received
more benefit of apoptosis protection from sotid phase EFNB1, and were more susceptible
to apoptosis after the putative EFNBY and EFNB1R interaction was disrupted by soluble
EFNB1-Fc. Overaïl, this mode! is more appealing, suggesting that the physiological role of
EFNB 1 in the thymus is to promote thymocyte surviva! by delivering anti-apoptotic signals
to EfNB1R-bearing celis, notably CD8 SP and DP cefls, which had high levels ofEFNBYR
expression.
How do we explain that CD8 cells, which manifested most extensive EFNBI-Fc-triggered
apoptosis, had most significant population increase in FTOC, while DP cells, which were
also vulnerable to soluble EFNB- I Fc, showed the sharpest population decrease in FTOC?
FTOC is a very complex system, in which proliferation, differentiation, apoptosis, and
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apoptotic cell removal occur at the sarne time; the cell populations we observed after FTOC
is the sum ofthese events. The relative increase ofCD8 SP celi could well be that new CD8
SP generation outweighs their apoptosis; the relative decrease of DP population could be
due to that their apoptosis outweighs their replenishment. for CD4 SP cells, they are flot
drastically affected by EFNB1-Fc in ternis of apoptosis and proliferation. The increase of
their population after FTOC is likely a relative one due to the changes of other populations.
We could flot exclude the possibility that in fTOC, soluble EFNB 1 promotes extinguishing
of CD4 or CD8 expression in DP celis, and this leads to the consequent of SP increase and
DP decrease. However, such an effect, even if exists at ail, cannot be the major mechanism
responsible for skewed subpopulations, because it could not explain the augmented
proliferation of most thymocyte subpopulations and increased CD8 SP apoptosis in the
presence of soluble EFNB1 in FTOC. Moreover, no rapid conversion ofDP to SP cells was
found in isolated thymocyte culture in the presence of soluble EFNB1 (data not shown).
Soluble EFNB1-induced apoptosis ofisolated thymocytes is presumably due to interruption
of the positive interaction between EFNB1 and EFNB1R. As solid phase EFNB1 could
protect the thymocytes from apoptosis, which was demonstrated in this study and supported
in a previous publication by Roifman’s group (36), it is reasonable to speculate that the
thymocyte survival depends on signals flowing ftom endogenous EfNB 1 to EFNB 1 R. In
neurons, some EfNBs and EphBs are capable of stimulating each other reciprocally (37-
39). Whether EFNBÏ on thymocytes can reversely receive signals from EFNBIR, and
soluble EFNB1-Fc can cause apoptosis by interrupting such putative reverse signaling are
to be further investigated. With that said, we did tested a couple of EphB family molecules
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(e.g., EphB6 and EphB4) on solid phase for T-ceil suiwival and proliferation, but no effect
was detected (data not shown).
Our study further dernonstrated that TCR-crossiinking lcd to congregation of 1CR and
EFNB1R into rafts, and EFNBR crossiinking enhanced 1CR signaling, as evidenced by
augmented LAT and cbi phosphorylation. As thymocytes need to be positiveiy selected
based on TCR signaling strength, the physiological role of EFNB1R in highly EFNB1R
positive ceils, such as DP ceils, might be to raise weak TCR signaling to a level over the
threshold of positive selection, and thus aÏlow the survival of these ceils. The high
expression ofEFNB1R on CD8 SP ceils, and the preferential protective role of solid phase
EFNB I to this population is an interesting observation. Obviousiy, SP celis have aiready
passed the positive selection period, according to previous reports (40-42). Thus, it seems
that EfNB1R might also function as a general trophic factor to enhance the survival of
thymocytes. It does not necessariiy mean that CD4 SP celis, which do flot have high
EFNB 1R expression, do flot need trophic support, but they might depend on other
molecules.
We have reported here that solid phase EfNB 1 can deliver survival signais through
EFNB 1 R expressed on thymocytes, and blocking EFNB 1 and EFNB I R drasticaily aiters
the balance ofthymocyte populations in FTOC. Due to the inherited limitation offTOC, in
which apoptosis, apoptotic ccli removal, putative compensatory ccii growth, and phenotype
switch could not be individually dissected, we can only use logical reasoning to deduce the
role of EFNB 1 in T-ecu development. To ultimateiy conflrm what we have deduced, i.e.,
EFNB I preferentially prornotes positive selection and acts as a trophic factor for certain T-
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ceil subpopulations with higli EFNB1R expression, EFNBY nul! mutation will be needed.
Indeed, we have generated EFNB 1 knockout mice, and preliminary resuits disclosed that
these mice were significantly compromised in thymic T-cefl development, with atrophic
thymus (data not shown).
Through recent studies of ours and several other groups, the important roles of Eph kinases
and their ligands, EFNs, in the immune system are emerging; more work in this new
dimension ofT-cell biology is warranted.
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Figure 1. EFNBJ and EFNBJR expression in the thymus
A. In situ hybridization anaÏysis of thymus EFNBÏ expression
The aduit BALB/c thymus was hybridized with DIG-labeled anti-sense or sense riboprobes
ofEFNB1. Original magnification is lOx. S: subcapsule region; C, cortex, M: medulla.
B. Flow cytornet,y analysis oJEFNBJ an1 EFNB]R expression on thymocytes
Three-color flow cytometry was used to assess EFNEÎ and EFNB3, or EFNB1R and
EFNB3R expression on E17 fetal thymocyte subpopulations. Normal goat IgG and human
IgG were sewed as controls for goat-anti-EFNB Abs and EfNB-Fc, respectively. These
controls are shown as shaded areas; such background staining has been deducted from the
percentage shown. The experiment was performed more than tbree times, and
representative histograms are depicted.
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figure 2. Soluble EFNBJ-Fc skews thyrnocyte subpopulations in fTOC
Thymuses from e 17 BALB/c fetuses were cultured for the durations as indicated. EFNB 1-
Fc, EFNB2-Fc, EFNB3-Fc or NHIgG (ail at 10 tg/m1) was added to the culture. Every 2-3
days, about 50% of the medium was replaced with ftesh medium containing the same
reagents. The experiment was conducted more than 3 times, and representative data are
shown.
A. EfNBJ-fc rapidly enters fTOC
In the left panel, fresh thymocytes from e17 thymus were stained with EFNB1-Fc followed
by goat anti-human IgG-PE. In the right panel, EFNB1-Fc was added to e17 FTOC
ovemight, and the thymocytes was flushed out and stained directly with goat anti-human
IgG-PE. NHIgG was used as controls (shaded area). Histograms of 1-color flow cytometiy
are shown. EFNB1R percentage above the background staining is indicated.
B and C. EfNBJ-fc aÏters the ratio ofthymocyte subpopulations in FTOC
FTOC was conducted for 10 day (B) or 5 days (C) in the presence of EFNB1, 2 or 3, or
NHIgG, as indicated. Thymocytes from FTOC were analyzed by 2-color flow cytometry for
CD4 and CD$ expression. The percentages of DN, DP, CD4 SP and CD8 SP ceils are
indicated.
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Figure 3. Soluble EFNB] influences pmflferation and apoptosis ofthymocytes in FTOC
FTOC of e17 BALB/c thymuses was performed in the presence of BrdU (30 tg!m1) along
with various EFNBs and NHIgG as indicated. The experiment was conducted more than 3
times, and representative resuits are shown.
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A. BrdU uptake by thyrnocytes after 10 days in FTOC
Thymocytes from FTOC without BrdU were stained with FITC-anti-BrdU mAb to
establish the background of BrdU staining (shaded area). Two- or three-color flow was
employed to assess BrdU uptake of DN, CD25, CD1 17, DP, CD4 SP and CD8 SP ceils
after lO-day FTOC. Percentage ofBrdU positive ceils in different subpopulations is shown.
B. Apoptosis ofthymocytes after 10 days in FTOC
After lO-day FTOC in the presence ofEFNB1-Fc, EfNB3-fc or HNIgG, thymocytes were
reacted with Annexin V-FITC, anti-CD4 and anti-CD8, and analyzed by 3-color flow
cytometry. Fresh e 17 thymocytes were stained with Annexin V-FITC to determine the
background of Annexin V staining (shaded area). Percentages of Annexin V positive celis
in different subpopulations are shown.
C. Cetlutarity of fTOC afler dtfferent days ofcittture
After 5, 10 or 12 days of FTOC in the presence of EFNB1-Fc, EfNB3-Fc or NHIgG,
thymocytes were flushed out and counted by flow cytometry. The celluiarity of each
thymus lobe was then calculated. Mean ± SD of ccli number/lobe of 5-10 lobes from 3
independent experiments are illustrated.
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Figure 4. Effect ofsoÏid phase and soluble EFNB1-Fc on thymocyte sun’ival in vitro
E17 thyrnocytes were isolated and cultured in the presence of solid phase anti-CD3 mAb
plus solid or soluble phase EFNB 1 -Fc for 20 h. Apoptosis of different subpopulations was
analyzed by 3-color flow cytometry according to Annexin V-HTC staining. NHIgG served
as control (shaded area) for EFNB1-Fc; EfNB3-Fc, for comparison. Fresh thyrnocytes
were stained with Annexin V-FITC to determine the Annexin V negative gating.
Percentages of Annexin V positive ceils are indicated. The experiment was conducted more
than 3 tirnes, and representative resuits are shown.
A. Solidphase EFNBJ-Fc inhibits anti-CD3-induced thymocyte apoptosis
Isolated thymocytes were cultured in welÏ coated with higli-dose solid phase anti-CD3 mAb
(clone 2C11, 20 tg/rnl during coating). EfNBÏ-Fc, EFNB3-Fc orNHIgG was also present
during the coating (all at 20 jtg/rnl). After 20h, different thymocyte subpopulations were
analyzed for Annexin V positiveness by flow cytometry.
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B. EFNB]-Fc in solution augments thymocyte apoptosis
Isolated thymocytes were cultured in the presence of low-dose solid phase anti-CD3 (clone
2C1 1, 2 Ig!ml for coating), and soluble EFNB1-Fc, EFNB3-Fc or NHIgG (ah at 10 jig/ml)
for 20 h. Different thymocyte subpopulations were then analyzed for Annexin V binding by
flow cytometry.
Fig. 5
TC R EFNB1R Overlay TCR EFNB1R Overlay
Figure 5. Rapid co-localization oJEFNB1R with TCR and raft caps after anti-CD3- and
CD4- crosslinking
Aduit BALB/c thymocytes were crosslinked with anti-CD3 for O orlO mm, as indicated.
The locations of 1CR (stained with biotin-anti-CD3 and biotin-anti-CD4 foliowed by Alexa
Fluor 594-streptavidin in red) (A), EFNB1R (stained with EFNB1-Fc foliowed by Alexa
488-anti-human IgG in green) (A and B), and rafis (stained with Alexa fluor 594—choiera
Raft EFNB1R Overlay Raft EFNB1R Overlay
Omn lOmin
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toxin (CT) in red) (B) were revealed by confocal microscopy. The experiment was repeated
twice, and a set of representative photos is shown.
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Figure 6. PhosphoiyÏation ofLA T and cbl in thyrnocytes alter EFNB]R crosslinking
Aduit BALB/c thymocytes were first incubated on ice with anti-CD3 (2C 11, hamster
mAb), and EFNB I -Fc or NHIgG, as indicated; the celis were then reacted on ice with goat
anti-hamster IgG and anti-human IgG; crosslinking was conducted at 37°C for 1.5 min.
A. Phosphoiylation ofLAT
LAI Phosphorylation was detected with anti-phospho-LAT Ah. The membrane was
reprobed with anti-LAT Ah to detect total LAT protein, which indicates sirnilar protein
loading in each lane.
B. PhosphoiyÏation ofcbÏ
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Cbl was immunoprecipitated with anti-cbl Ah. Phosphoryfated Chi was detected by
immunoblotting, using anti-phosphoprotein mAb (PY-20). Total chi protein in each lane
was revealed by reprobing the membrane with anti-cbl Ah.
The experiments were repeated at least 3 times, and representative data are shown.
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUANGYU 152
III. DISCUSSION
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DISCUSSION
In this project, we studied the functions of EFNBs and of their receptors, EfNBRs, in mouse
T ceil development and activation. Our data revea!ed that both ligands and receptors are
expressed in peripheral lymphocytes and monocytes/macrophages, with T ceils expressing
the highest levels of EFNBs and EFNBRs. So!id phase EfNBs-Fc in the presence of
suboptirnal anti-CD3 crosslinking can enhance T-cell responses in terms of proliferation,
activation marker expression, IFN-y production, and cytotoxic T-ce!! activity. Upon TCR
crosslinking, EfNBRs congregate into aggregated lipid rafts, to which TCR a!so transiocates.
This provides a morphologica! basis for EFNRs to enhance TCR signaling. Downstream
from the ce!! surface TCR, EfNBR signaling augments p38 and p44142 MAPK activation in
T cells. In the thymus, EFNB 1 and its receptors have high levels of expression in DP and
CD8 SP popu!ations. EfNB! in solid phase inhibits apoptosis of high EfNB 1 R-expressing
populations, i. e., CD8 SP fo!lowed by DP ceils. In contrast, solub!e EFNBY augments
apoptosis of these ceils. These findings suggest that the endogenous EfNB 1 and EfNB ! R
interaction is pivotal for thymocyte survival. When soluble EfNB! is present in FTOC, there
is augmentation of CD4 S but a decrease of DP popu!ation through a complex homeostatic
process.
1. Functional redundancy suggests biological importance of Ephs and EFNs
In vitro, EFNB2 and EFNB3 co-stimulate T ce!! activation to a simi!ar degree. EFNB 1 has
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similar effects in this regard (data not shown). These observations are consistent with the
highly conserved molecular structures of the three molecules (299, 5), and the overlapping
spectrum of their receptors (fig. 2). The similar expression pattems together with the
functional redundancy of these EFNBs suggest the biological importance of EFNBs and of
their receptors in maintaining proper T ce!! function, because such redundancy is the
safeguard against !ethal consequences due to loss of function of any member. On the other
hand, such redundancy represents a challenge to our reductionist approach to analyze the
function of these molecu!es. for example, we have investigated the immune system of
EfNB3 knockout mice, but no significant in vitro or in vivo defects cou!d be found (data not
shown), suggesting compensation from other members of the family. Simultancous
inactivation oftwo or more members ofthe family might be required to reveal their function.
Our unpub!ished data showed that so!id phase EfNBs co-stimu!ate T ce!l activation, but such
an effect cou!d not be b!ocked by soluble EfNB4, a receptor of EfNBs. The b!ocking effect
of EphB4 was only apparent when EphB6 was mutated, suggesting that EphB4 and EphB6
have functional redundancy in receiving EfNB2 stimulation.
However, different EfNB members do have distinct expression and functional differences.
For examples, EfNB 1 is more highly expressed on B cells than EFNB2 and EFNB3; soluble
EfNB1-Fc but flot EfNB2 -fc or EfNB3-Fc has potent effect on T-cel! development in the
thymus during feta! thymus organ culture (fTOC). These distinct features allow EfNBs and
their receptors to regulate different aspects of T-cell development and activation.
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2. Biotogical significance of EFNBs-EFNBRs in aduit T ceits
Packaging lymphocytes into defined anatomic locations of secondary lymphoid organs is
thought to favor their interactions with antigen-presenting celis and perhaps other regulatory
ceils, and to provide a framework which permits rapid circulation of naïve ceils through a
space where antigens are concentrated, thus enhancing the efficiency of immune responses.
To induce full activation of T ceils, co-stimulation is necessary. Co-stimulation molecules
play a crucial role in T celi activation (178), proliferation (179), and differentiation to
effector celis (180). The co-stimulatory molecules, e.g., CD28 and TNF family, have been
well documented. However, besides the co-stimulation provided by the molecules from so
called accessory celis, we know littie about the other T celi surface molecules that can supply
mutual stimulation. One of the fundamental features ofco-stimulatory molecules is to reduce
the threshold of T ccli activation, for example, it has been shown that the presence of CD28
results in a reduction in the threshold number of activated 1CR from 8000 to 1500 to achieve
T celi activation (300). In vitro smdies have demonstrated that in the absence of CD28
engagement, T ceils require very high TCR occupancy and prolonged stimulation, whereas
CD28 co-stimulation allows T cells to respond to lower degrees of TCR occupancy (300,
301). The T-cell-T-cell collaboration is not a well-investigated topic in irnmunology, but it
lias recently drawn certain attention. Wang et al. have demonstrated that the T-cell-surface
molecule LIGHT, which is a ligand belonging to the TNf superfamily, can enhance T-cell
response via its receptor HveA on T ceils in a pure T-cell culture system (262); this is an
indication that 1-ceil-T-ceIl cooperation is important for optimal T ccii response. We have
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shown here that both EFNBs and EfNBRs are expressed on T ceils, and that solid phase
EFNBs can activate purified T celis in the presence of suboptimal levels of anti CD3,
suggesting that T ceils can receive co-stimulation from fe!!ow T celis, and that
EfNBs/EFNBRs are nove! pairs of molecu!es involved in T-ce!!-T-ce!! cooperation. It is
conceivab!e that in lymphoid organs, tightly packed T celis constantly interact with each
other through EFNBs and EFNBRs; as a consequence, the T-ce!! response thresho!d is
!owered, as our in vitro data suggested. Naturally, the neighbouring ce!!s cou!d a!so be other
EFNB-expressing ceils, e.g., monocytes/macrophages, or B ce!!s. Considering the
documented expression of some EphB/EFNB members on endothelia! ce!ls (33, 68), it is
reasonable to specu!ate that the interaction between these !igands and receptors have
consequences beyond T ce!1 activation. Indeed, EfNB !igands have been found to modify the
chemotactic responses of a T ccli une and primaiy T cells (78).
3. Biological significance of EFNB1-EFNB1R in thymocyte development
We have demonstrated that EfNB! and EFNB 1 R are predominant!y expressed on CD$ $P
and DP subpopu!ations of thymocytes; solid phase EFNB 1 can deliver surviva! signa!s
through EFNB1R expressed on thymocytes, and blocking EfNB! and EFNB1R drastically
a!ters the ba!ance ofthymocyte populations in FTOC.
Thymocytes need to go through extensive selection processes during their development in
the thymus. The outcome of the selection is believed to be dctermined by the strength of
interactions between the TCR comp!ex on thymocytes and their ligands on thymic antigen
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presenting ceils (157, 302). The cunent consensus is that thymocytes receiving a moderate
strength 1CR signal are positively selected and develop further into mature T celis, whereas
ceils receiving too weak signais will be eliminated by positive selection, and those receiving
too strong signais will commit apoptosis by negative seiection.
According to our in vitro data, solid phase EfNB1 inhibited thymocyte apoptosis; on the
other hand, soluble EfNB1-fc caused increased apoptosis of isolated thymocytes,
presumably due to its interference to the endogenous EfNB1 and EfNB1R interaction
between thymocytes. In addition, cornpared to the low EfNB 1 R expressing subpopulations,
the thymocyte subpopulations expressing high EFNB 1 R received more benefit of apoptosis
protection from solid phase EFNB 1, and were more susceptible to apoptosis after the
putative interaction between EFNBÏ and EFNBÏR was disrupted by soluble EfNB1-fc. As
thymocytes need to be positively seiected based on the TCR signaling strength, the
physioiogical role of EFNB1R on highly EFNB1R positive ceils, such as DP celis, might be
to raise the weak 1CR signaling to a levei over the threshold of positive selection, and thus
allow survival of these cells. Considering that EFNBs can enhance MAPK activation in
peripheral T celis (106, 107, 108), and that MAPK activation delivers a major survivai signal
in CD4CD8 DP cells (302, 303), it seems that EfNB1R may aiso function to moduiate 1CR
signaiing in a manner that prevents induction of apoptosis by iow-affinity 1CR interactions.
However, SP ceils have already passed the positive selection period. The high expression of
EFNB I R on CD8 SP ceiis, and the preferentiai protective role of solid phase EFNB 1 with
respect to this population is an interesting observation. Ail these data imply that the
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physiological role of EFNB 1 in the thymus is to promote thymocyte survival by delivering
anti-apoptotic signais to EFNB1R-bearing ceils, notabiy CD8 SP and DP ceils, which had
high leveis ofEFNBYR expression. 0f course, this does flot necessarily mean that CD4 SP
ceils, which do not have high EfNB1R expression, do flot need protection, but they might
depend on other moiecuies for that purpose. It is reasonabie to assume that the soluble
EFNB 1 -induced apoptosis of isoiated thymocytes is due to interruption of the positive
interaction between EFNB 1 and EFNB 1 R.
4. The contribution of this study to science
We have studied the immunological function of EFNBs and EFNBRs interactions, and
revealed previousiy undocumented features of these moiecules in T-ceil regulation. It is the
first extensive study ofEfNB members in the immune system in terms oftheir expression in
different immune cell population, function in T ceil stimulation, and their effect on T ceil
deveiopment. Our resuits showed that there is significant functional similarity among the
three EFNB members, suggesting that these moiecules have overiapping but essential
functions in T-cell activation. Our findings ied to a new direction in our quest for a better
understanding of T ccii bioiogy. Furthermore, our study has provided a rationaie to use
EFNBs and EphBs as therapeutic targets in immune disorders.
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